<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:08:58Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6312377" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6312377</identifier>
        <datestamp>2019-01-08</datestamp>
        <setSpec>plosone</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
              <journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id>
              <journal-id journal-id-type="publisher-id">plos</journal-id>
              <journal-id journal-id-type="pmc">plosone</journal-id>
              <journal-title-group>
                <journal-title>PLoS ONE</journal-title>
              </journal-title-group>
              <issn pub-type="epub">1932-6203</issn>
              <publisher>
                <publisher-name>Public Library of Science</publisher-name>
                <publisher-loc>San Francisco, CA USA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6312377</article-id>
              <article-id pub-id-type="pmcid">PMC6312377</article-id>
              <article-id pub-id-type="pmc-uid">6312377</article-id>
              <article-id pub-id-type="pmid">30596792</article-id>
              <article-id pub-id-type="doi">10.1371/journal.pone.0210128</article-id>
              <article-id pub-id-type="publisher-id">PONE-D-18-28639</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Immune System Proteins</subject>
                      <subj-group>
                        <subject>Inflammasomes</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Immune System Proteins</subject>
                      <subj-group>
                        <subject>Inflammasomes</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Biochemistry</subject>
                    <subj-group>
                      <subject>Proteins</subject>
                      <subj-group>
                        <subject>Immune System Proteins</subject>
                        <subj-group>
                          <subject>Inflammasomes</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Biochemistry</subject>
                    <subj-group>
                      <subject>Biomarkers</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Critical Care and Emergency Medicine</subject>
                    <subj-group>
                      <subject>Trauma Medicine</subject>
                      <subj-group>
                        <subject>Traumatic Injury</subject>
                        <subj-group>
                          <subject>Neurotrauma</subject>
                          <subj-group>
                            <subject>Traumatic Brain Injury</subject>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Anatomy</subject>
                    <subj-group>
                      <subject>Body Fluids</subject>
                      <subj-group>
                        <subject>Cerebrospinal Fluid</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Anatomy</subject>
                    <subj-group>
                      <subject>Body Fluids</subject>
                      <subj-group>
                        <subject>Cerebrospinal Fluid</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Physiology</subject>
                    <subj-group>
                      <subject>Body Fluids</subject>
                      <subj-group>
                        <subject>Cerebrospinal Fluid</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Physiology</subject>
                    <subj-group>
                      <subject>Body Fluids</subject>
                      <subj-group>
                        <subject>Cerebrospinal Fluid</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Anatomy</subject>
                    <subj-group>
                      <subject>Nervous System</subject>
                      <subj-group>
                        <subject>Cerebrospinal Fluid</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Anatomy</subject>
                    <subj-group>
                      <subject>Nervous System</subject>
                      <subj-group>
                        <subject>Cerebrospinal Fluid</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Biochemistry</subject>
                    <subj-group>
                      <subject>Proteins</subject>
                      <subj-group>
                        <subject>Serum Proteins</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Immune Response</subject>
                      <subj-group>
                        <subject>Inflammation</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Immune Response</subject>
                      <subj-group>
                        <subject>Inflammation</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Diagnostic Medicine</subject>
                    <subj-group>
                      <subject>Signs and Symptoms</subject>
                      <subj-group>
                        <subject>Inflammation</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Pathology and Laboratory Medicine</subject>
                    <subj-group>
                      <subject>Signs and Symptoms</subject>
                      <subj-group>
                        <subject>Inflammation</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Critical Care and Emergency Medicine</subject>
                    <subj-group>
                      <subject>Trauma Medicine</subject>
                      <subj-group>
                        <subject>Traumatic Injury</subject>
                        <subj-group>
                          <subject>Head Injury</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Neurology</subject>
                    <subj-group>
                      <subject>Brain Damage</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Inflammasome proteins as biomarkers of traumatic brain injury</article-title>
                <alt-title alt-title-type="running-head">Inflammasome and TBI biomarkers</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kerr</surname>
                    <given-names>Nadine</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Conceptualization</role>
                  <role content-type="http://credit.casrai.org/">Formal analysis</role>
                  <role content-type="http://credit.casrai.org/">Investigation</role>
                  <role content-type="http://credit.casrai.org/">Methodology</role>
                  <role content-type="http://credit.casrai.org/">Writing – original draft</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lee</surname>
                    <given-names>Stephanie W.</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Conceptualization</role>
                  <role content-type="http://credit.casrai.org/">Data curation</role>
                  <role content-type="http://credit.casrai.org/">Investigation</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Perez-Barcena</surname>
                    <given-names>Jon</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Conceptualization</role>
                  <role content-type="http://credit.casrai.org/">Data curation</role>
                  <role content-type="http://credit.casrai.org/">Formal analysis</role>
                  <role content-type="http://credit.casrai.org/">Investigation</role>
                  <role content-type="http://credit.casrai.org/">Methodology</role>
                  <role content-type="http://credit.casrai.org/">Project administration</role>
                  <role content-type="http://credit.casrai.org/">Writing – original draft</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-0781-9708</contrib-id>
                  <name>
                    <surname>Crespi</surname>
                    <given-names>Catalina</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Data curation</role>
                  <role content-type="http://credit.casrai.org/">Investigation</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff004">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-3735-8332</contrib-id>
                  <name>
                    <surname>Ibañez</surname>
                    <given-names>Javier</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Data curation</role>
                  <role content-type="http://credit.casrai.org/">Investigation</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff005">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bullock</surname>
                    <given-names>M. Ross</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Conceptualization</role>
                  <role content-type="http://credit.casrai.org/">Investigation</role>
                  <role content-type="http://credit.casrai.org/">Methodology</role>
                  <role content-type="http://credit.casrai.org/">Project administration</role>
                  <role content-type="http://credit.casrai.org/">Resources</role>
                  <role content-type="http://credit.casrai.org/">Supervision</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff006">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dietrich</surname>
                    <given-names>W. Dalton</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Conceptualization</role>
                  <role content-type="http://credit.casrai.org/">Funding acquisition</role>
                  <role content-type="http://credit.casrai.org/">Methodology</role>
                  <role content-type="http://credit.casrai.org/">Resources</role>
                  <role content-type="http://credit.casrai.org/">Writing – original draft</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff006">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Keane</surname>
                    <given-names>Robert W.</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Conceptualization</role>
                  <role content-type="http://credit.casrai.org/">Funding acquisition</role>
                  <role content-type="http://credit.casrai.org/">Investigation</role>
                  <role content-type="http://credit.casrai.org/">Methodology</role>
                  <role content-type="http://credit.casrai.org/">Resources</role>
                  <role content-type="http://credit.casrai.org/">Software</role>
                  <role content-type="http://credit.casrai.org/">Supervision</role>
                  <role content-type="http://credit.casrai.org/">Writing – original draft</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-5460-8834</contrib-id>
                  <name>
                    <surname>de Rivero Vaccari</surname>
                    <given-names>Juan Pablo</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Conceptualization</role>
                  <role content-type="http://credit.casrai.org/">Formal analysis</role>
                  <role content-type="http://credit.casrai.org/">Investigation</role>
                  <role content-type="http://credit.casrai.org/">Methodology</role>
                  <role content-type="http://credit.casrai.org/">Project administration</role>
                  <role content-type="http://credit.casrai.org/">Software</role>
                  <role content-type="http://credit.casrai.org/">Supervision</role>
                  <role content-type="http://credit.casrai.org/">Validation</role>
                  <role content-type="http://credit.casrai.org/">Visualization</role>
                  <role content-type="http://credit.casrai.org/">Writing – original draft</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff006">
                    <sup>6</sup>
                  </xref>
                  <xref ref-type="corresp" rid="cor001">*</xref>
                </contrib>
              </contrib-group>
              <aff id="aff001">
                <label>1</label>
                <addr-line>Department of Neurological Surgery, Neuroscience Program, The Miami Project to Cure Paralysis, University of Miami Miller School of Medicine, Miami, FL, United States of America</addr-line>
              </aff>
              <aff id="aff002">
                <label>2</label>
                <addr-line>Department of Physiology and Biophysics, University of Miami Miller School of Medicine, Miami FL, United States of America</addr-line>
              </aff>
              <aff id="aff003">
                <label>3</label>
                <addr-line>Intensive Care Department, Son Espases Hospital, Palma de Mallorca, Spain</addr-line>
              </aff>
              <aff id="aff004">
                <label>4</label>
                <addr-line>Fundacio Institut d’Investigacio Sanitaria Illes Balears (IdISBa), Son Espases Hospital, Palma de Mallorca, Spain</addr-line>
              </aff>
              <aff id="aff005">
                <label>5</label>
                <addr-line>Department of Neurological Surgery, Son Espases Hospital, Palma de Mallorca, Spain</addr-line>
              </aff>
              <aff id="aff006">
                <label>6</label>
                <addr-line>Department of Neurological Surgery, The Miami Project to Cure Paralysis, University of Miami Miller School of Medicine, Miami, FL, United States of America</addr-line>
              </aff>
              <contrib-group>
                <contrib contrib-type="editor">
                  <name>
                    <surname>Ojcius</surname>
                    <given-names>David M.</given-names>
                  </name>
                  <role>Editor</role>
                  <xref ref-type="aff" rid="edit1"/>
                </contrib>
              </contrib-group>
              <aff id="edit1">
                <addr-line>University of the Pacific, UNITED STATES</addr-line>
              </aff>
              <author-notes>
                <fn fn-type="COI-statement" id="coi001">
                  <p><bold>Competing Interests: </bold>JPdRV, RWK and WDD are co-founders and managing members of InflamaCORE, LLC and have patents on inflammasome proteins as biomarkers of injury and disease as well as on targeting inflammasome proteins for therapeutic purposes. Data presented in this manuscript is protected under US Patent Application: 62/560,963 (Method for Detecting Inflammasome Proteins as Biomarkers of Neurological Disorders). This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.</p>
                </fn>
                <corresp id="cor001">* E-mail: <email>JdeRivero@med.miami.edu</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>31</day>
                <month>12</month>
                <year>2018</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2018</year>
              </pub-date>
              <volume>13</volume>
              <issue>12</issue>
              <elocation-id>e0210128</elocation-id>
              <history>
                <date date-type="received">
                  <day>2</day>
                  <month>10</month>
                  <year>2018</year>
                </date>
                <date date-type="accepted">
                  <day>17</day>
                  <month>12</month>
                  <year>2018</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2018 Kerr et al</copyright-statement>
                <copyright-year>2018</copyright-year>
                <copyright-holder>Kerr et al</copyright-holder>
                <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="pone.0210128.pdf"/>
              <abstract>
                <sec id="sec001">
                  <title>Background</title>
                  <p>The inflammasome plays an important role in the inflammatory innate immune response after central nervous system (CNS) injury. Inhibition of the inflammasome after traumatic brain injury (TBI) results in improved outcomes by lowering the levels of caspase-1 and interleukin (IL)-1b. We have previously shown that inflammasome proteins are elevated in the cerebrospinal fluid (CSF) of patients with TBI and that higher levels of these proteins were consistent with poorer outcomes after TBI when compared to patients that presented these inflammasome proteins at lower levels.</p>
                </sec>
                <sec id="sec002">
                  <title>Methods and findings</title>
                  <p>Here we extend our work by analyzing serum from 21 TBI patients and CSF from 18 TBI patients compared to 120 serum samples and 30 CSF samples from no-TBI donor controls for the expression of caspase-1, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), interleukin(IL)-1b and IL-18. Analysis was carried out using the Ella Simple Plex system (Protein Simple) to determine the sensitivity and specificity of inflammasome proteins as biomarkers of TBI. Receiver operator characteristic (ROC) curves, confidence intervals and likelihood ratios for each biomarker was determined. ROC curves, confidence intervals, sensitivity and specificity for each biomarker examined revealed that caspase-1 (0.93 area under the curve (AUC)) and ASC (0.90 AUC) in serum and ASC (1.0 AUC) and IL-18 (0.84 AUC) in CSF are promising biomarkers of TBI pathology. Importantly, higher protein levels (above 547.6 pg/ml) of ASC (0.91 AUC) were consistent with poorer outcomes after TBI as determined by the Glasgow Outcome Scale-Extended (GOSE).</p>
                </sec>
                <sec id="sec003">
                  <title>Conclusion</title>
                  <p>These findings indicate that inflammasome proteins are excellent diagnostic and predictive biomarkers of TBI.</p>
                </sec>
              </abstract>
              <funding-group>
                <award-group id="award001">
                  <funding-source>
                    <institution>NIH</institution>
                  </funding-source>
                  <award-id>4R42NS086274-012</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Keane</surname>
                      <given-names>Robert W.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award002">
                  <funding-source>
                    <institution>Fondo de Investigación Sanitaria</institution>
                  </funding-source>
                  <award-id>FIS PI16/00737</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Perez-Barcena</surname>
                      <given-names>Jon</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <funding-statement>This work was supported by a STTR grant (4R42NS086274-012) from the NINDS/NIH to RWK: <ext-link ext-link-type="uri" xlink:href="https://www.nih.gov/">https://www.nih.gov/</ext-link>; and by a public grant from Fondo de Investigación Sanitaria (FIS PI16/00737) to JPB: <ext-link ext-link-type="uri" xlink:href="https://portalfis.isciii.es/es/Paginas/inicio.aspx">https://portalfis.isciii.es/es/Paginas/inicio.aspx</ext-link>. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
              </funding-group>
              <counts>
                <fig-count count="6"/>
                <table-count count="8"/>
                <page-count count="16"/>
              </counts>
              <custom-meta-group>
                <custom-meta id="data-availability">
                  <meta-name>Data Availability</meta-name>
                  <meta-value>The data underlying the results presented in the study are found in the supporting information of this manuscript.</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <title>Data Availability</title>
              <p>The data underlying the results presented in the study are found in the supporting information of this manuscript.</p>
            </notes>
          </front>
          <body>
            <sec sec-type="intro" id="sec004">
              <title>Introduction</title>
              <p>A biomarker is a surrogate indicator of biological processes occurring in an individual. Biomarkers provide information about the pathology of a disease or condition, as well as the response to a pathogen or treatment. In the context of traumatic brain injury (TBI), biomarkers have the potential to be used as diagnostic markers of injury severity, as well as markers of response to treatment (monitoring biomarkers) or even as predictors of outcomes after trauma (predictive biomarkers).</p>
              <p>Recently, the Brain Trauma Indicator has been authorized by the FDA to evaluate concussion in adults. This indicator is obtained by measuring the levels of ubiquitin C-terminal hydro-lase–L1 (UCH-L1) and glial acidic fibrillary protein (GFAP) in blood within 12 hours after trauma [<xref rid="pone.0210128.ref001" ref-type="bibr">1</xref>–<xref rid="pone.0210128.ref003" ref-type="bibr">3</xref>]. Other promising biomarkers have been suggested for diagnosis, monitoring and prognosis of traumatic brain injury (TBI) such as microtubule-associated protein-2 (MAP2, neuron-specific enolase (NSE), myelin basic protein (MBP), tau, s100β and neurofilament heavy chain protein (NF-H) [<xref rid="pone.0210128.ref004" ref-type="bibr">4</xref>–<xref rid="pone.0210128.ref006" ref-type="bibr">6</xref>]. However, these proteins are yet to be approved for the clinical care of TBI patients. In addition, heart fatty acid binding protein (H-FABP), when combined with interleukin (IL)-10, S100β and GFAP, has been shown to be elevated in patients positive for brain damage as determined by a head CT scan [<xref rid="pone.0210128.ref007" ref-type="bibr">7</xref>].</p>
              <p>The innate immune response is a significant contributor to inflammation after TBI that is regulated by inflammasomes. To date several inflammasomes have been shown to play a role in the inflammatory response in the nervous system. For instance, the first inflammasome to be described in the nervous system was the NLRP1 inflammasome that is activated in neurons after spinal cord injury [<xref rid="pone.0210128.ref008" ref-type="bibr">8</xref>], brain injury [<xref rid="pone.0210128.ref009" ref-type="bibr">9</xref>] and stroke [<xref rid="pone.0210128.ref010" ref-type="bibr">10</xref>]. Moreover, the NLRP2 inflammasome in astrocytes has been shown to be involved in the inflammatory response after ATP stimulation [<xref rid="pone.0210128.ref011" ref-type="bibr">11</xref>]. The most studied inflammasome is the NLRP3 inflammasome and is is present in microglia and astrocytes [<xref rid="pone.0210128.ref012" ref-type="bibr">12</xref>–<xref rid="pone.0210128.ref014" ref-type="bibr">14</xref>]. Additionally, the NLRC4 inflammasome is present in astrocytes [<xref rid="pone.0210128.ref014" ref-type="bibr">14</xref>], and the AIM-2 inflammasome in neurons [<xref rid="pone.0210128.ref015" ref-type="bibr">15</xref>]. Inflammasome activation involves sensing of a particular trigger by cytosolic receptors such as NOD-like receptors (NLRs) or AIM-2 like receptors (ALRs). This activation process is triggered following the formation of large multiprotein complex called the inflammasome [<xref rid="pone.0210128.ref016" ref-type="bibr">16</xref>]. These inflammasome complexes undergo oligomerization that then serves as a platform to activate inflammatory caspases. However, some differences remain in that NLRP1 and NLRC4 can activate caspase-1 without ASC oligomerization, but ASC substantially improves the production of IL-1β. Thus, it is likely that inflammasomes that do not rely on ASC for assembly are less stable and as a result the inflammatory response mounted is weaker than it would be in the presence of ASC [<xref rid="pone.0210128.ref017" ref-type="bibr">17</xref>, <xref rid="pone.0210128.ref018" ref-type="bibr">18</xref>]. Inflammasomes process inflammatory cytokines such as interleukin(IL)-1β and IL-18 through the activation of caspase-1 [<xref rid="pone.0210128.ref018" ref-type="bibr">18</xref>]. We have previously shown that inflammasomes contribute to the pathology of TBI and that inhibition of the inflammasome results in decreased inflammation and improved histopathological outcomes after brain injury [<xref rid="pone.0210128.ref009" ref-type="bibr">9</xref>]. Moreover, inflammasome proteins are secreted after injury in extracellular vesicles isolated from serum [<xref rid="pone.0210128.ref019" ref-type="bibr">19</xref>] and CSF [<xref rid="pone.0210128.ref020" ref-type="bibr">20</xref>] that add to the systemic inflammatory response after trauma [<xref rid="pone.0210128.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0210128.ref021" ref-type="bibr">21</xref>].</p>
              <p>In this study, we provide receiver operator characteristic (ROC) curves with associated confidence intervals (CI) following analyses of serum and CSF samples from patients with TBI and from no-TBI control donors. In addition, we determine the sensitivity and specificity of inflammasome proteins to examine the potential of the inflammasome signaling proteins caspase-1, ASC, IL-1β and IL-18 as biomarkers of TBI.</p>
            </sec>
            <sec sec-type="materials|methods" id="sec005">
              <title>Methods</title>
              <sec id="sec006">
                <title>Participants</title>
                <p>Serum and CSF samples from patients with TBI and samples from no-TBI control donors were used in this study. Twenty-one TBI serum and 18 CSF samples were obtained after informed consent. Informed consent was obtained from a family member or proxy according to the University of Miami Miller School of Medicine IRB protocol # 20030154. All subjects were admitted to the Neurological Intensive Care Unit and/or the Ryder Trauma Center at Jackson Memorial Hospital (<bold><xref rid="pone.0210128.t001" ref-type="table">Table 1</xref></bold>). Samples from normal donors (120 samples) were purchased from Bioreclamation<italic>IVT</italic>. The normal donor group consisted of samples obtained from 60 male and 60 female donors in the age range of 20 to 70 years old (<bold><xref rid="pone.0210128.t002" ref-type="table">Table 2</xref></bold>). Thirty control CSF samples were obtained from Bioreclamation<italic>IVT</italic>. TBI Samples were collected three times a day for the first 5 days after patients arrived to the hospital. Samples were analyzed for the 1<sup>st</sup>, 2<sup>nd</sup> collection (Day 1) as well as 4<sup>th</sup> and 6<sup>th</sup> collections (Day 2). Later time points were analyzed but the data was not shown to be significant (data not shown).</p>
                <table-wrap id="pone.0210128.t001" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0210128.t001</object-id>
                  <label>Table 1</label>
                  <caption>
                    <title>Subjects with TBI.</title>
                  </caption>
                  <alternatives>
                    <graphic id="pone.0210128.t001g" xlink:href="pone.0210128.t001"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Age</th>
                          <th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Gender</th>
                          <th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Race</th>
                          <th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Mechanism of Injury</th>
                          <th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Injury</th>
                          <th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">GCS at resus</th>
                          <th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">GOSE</th>
                          <th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Outcome</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">81 (Deceased)</td>
                          <td align="center" rowspan="1" colspan="1">Female</td>
                          <td align="center" rowspan="1" colspan="1">White</td>
                          <td align="center" rowspan="1" colspan="1">Blunt injury</td>
                          <td align="center" rowspan="1" colspan="1">Contusion, IVH, tSAH</td>
                          <td align="center" rowspan="1" colspan="1">3</td>
                          <td align="center" rowspan="1" colspan="1">1</td>
                          <td align="center" rowspan="1" colspan="1">Deceased</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">26</td>
                          <td align="center" rowspan="1" colspan="1">Male</td>
                          <td align="center" rowspan="1" colspan="1">Unknown</td>
                          <td align="center" rowspan="1" colspan="1">Gunshot wound</td>
                          <td align="center" rowspan="1" colspan="1">Contusion, tSAH,</td>
                          <td align="center" rowspan="1" colspan="1">3</td>
                          <td align="center" rowspan="1" colspan="1">3</td>
                          <td align="center" rowspan="1" colspan="1">Unfavorable</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">29</td>
                          <td align="center" rowspan="1" colspan="1">Male</td>
                          <td align="center" rowspan="1" colspan="1">Black</td>
                          <td align="center" rowspan="1" colspan="1">s/p MCC with helmet</td>
                          <td align="center" rowspan="1" colspan="1">Contusion, DAI</td>
                          <td align="center" rowspan="1" colspan="1">3</td>
                          <td align="center" rowspan="1" colspan="1">6</td>
                          <td align="center" rowspan="1" colspan="1">Favorable</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">69 (Deceased)</td>
                          <td align="center" rowspan="1" colspan="1">Male</td>
                          <td align="center" rowspan="1" colspan="1">Black</td>
                          <td align="center" rowspan="1" colspan="1">Blunt injury</td>
                          <td align="center" rowspan="1" colspan="1">SDH, tSAH</td>
                          <td align="center" rowspan="1" colspan="1">8</td>
                          <td align="center" rowspan="1" colspan="1">1</td>
                          <td align="center" rowspan="1" colspan="1">Deceased</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">23</td>
                          <td align="center" rowspan="1" colspan="1">Male</td>
                          <td align="center" rowspan="1" colspan="1">White</td>
                          <td align="center" rowspan="1" colspan="1">MVA w/blunt injury</td>
                          <td align="center" rowspan="1" colspan="1">SDH, t SAH</td>
                          <td align="center" rowspan="1" colspan="1">3</td>
                          <td align="center" rowspan="1" colspan="1">2</td>
                          <td align="center" rowspan="1" colspan="1">Unfavorable</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">22</td>
                          <td align="center" rowspan="1" colspan="1">Male</td>
                          <td align="center" rowspan="1" colspan="1">Black</td>
                          <td align="center" rowspan="1" colspan="1">GSW to back of head</td>
                          <td align="center" rowspan="1" colspan="1">LSDH, contusion</td>
                          <td align="center" rowspan="1" colspan="1">4</td>
                          <td align="center" rowspan="1" colspan="1">8</td>
                          <td align="center" rowspan="1" colspan="1">Favorable</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">70</td>
                          <td align="center" rowspan="1" colspan="1">Male</td>
                          <td align="center" rowspan="1" colspan="1">White</td>
                          <td align="center" rowspan="1" colspan="1">Blunt injury/assault</td>
                          <td align="center" rowspan="1" colspan="1">SDH</td>
                          <td align="center" rowspan="1" colspan="1">10</td>
                          <td align="center" rowspan="1" colspan="1">3</td>
                          <td align="center" rowspan="1" colspan="1">Unfavorable</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">21 (Deceased)</td>
                          <td align="center" rowspan="1" colspan="1">Male</td>
                          <td align="center" rowspan="1" colspan="1">White</td>
                          <td align="center" rowspan="1" colspan="1">Blunt injury pedestrian struck by car w/head injury</td>
                          <td align="center" rowspan="1" colspan="1">SDH</td>
                          <td align="center" rowspan="1" colspan="1">3</td>
                          <td align="center" rowspan="1" colspan="1">1</td>
                          <td align="center" rowspan="1" colspan="1">Deceased</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">22</td>
                          <td align="center" rowspan="1" colspan="1">Male</td>
                          <td align="center" rowspan="1" colspan="1">White</td>
                          <td align="center" rowspan="1" colspan="1">Blunt injury punched to head and fell</td>
                          <td align="center" rowspan="1" colspan="1">SDH</td>
                          <td align="center" rowspan="1" colspan="1">4</td>
                          <td align="center" rowspan="1" colspan="1">6</td>
                          <td align="center" rowspan="1" colspan="1">Moderate</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">80 (Deceased)</td>
                          <td align="center" rowspan="1" colspan="1">Male</td>
                          <td align="center" rowspan="1" colspan="1">White</td>
                          <td align="center" rowspan="1" colspan="1">Penetrating injury, GSW to posterior head</td>
                          <td align="center" rowspan="1" colspan="1">Contusion, IVH</td>
                          <td align="center" rowspan="1" colspan="1">3</td>
                          <td align="center" rowspan="1" colspan="1">1</td>
                          <td align="center" rowspan="1" colspan="1">Deceased</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">71</td>
                          <td align="center" rowspan="1" colspan="1">Female</td>
                          <td align="center" rowspan="1" colspan="1">White</td>
                          <td align="center" rowspan="1" colspan="1">Blunt injury. MVC</td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1">3</td>
                          <td align="center" rowspan="1" colspan="1">1</td>
                          <td align="center" rowspan="1" colspan="1">Deceased</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">51 (Deceased)</td>
                          <td align="center" rowspan="1" colspan="1">Male</td>
                          <td align="center" rowspan="1" colspan="1">Black</td>
                          <td align="center" rowspan="1" colspan="1">Blunt injury, hit by car while biking</td>
                          <td align="center" rowspan="1" colspan="1">tSAH, contusion, IVH</td>
                          <td align="center" rowspan="1" colspan="1">3</td>
                          <td align="center" rowspan="1" colspan="1">1</td>
                          <td align="center" rowspan="1" colspan="1">Deceased</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">39 (Deceased)</td>
                          <td align="center" rowspan="1" colspan="1">Male</td>
                          <td align="center" rowspan="1" colspan="1">Unknown</td>
                          <td align="center" rowspan="1" colspan="1">MVA w/ blunt injury</td>
                          <td align="center" rowspan="1" colspan="1">tSAH, IVH</td>
                          <td align="center" rowspan="1" colspan="1">3</td>
                          <td align="center" rowspan="1" colspan="1">1</td>
                          <td align="center" rowspan="1" colspan="1">Deceased</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">18</td>
                          <td align="center" rowspan="1" colspan="1">Female</td>
                          <td align="center" rowspan="1" colspan="1">White</td>
                          <td align="center" rowspan="1" colspan="1">Blunt injury</td>
                          <td align="center" rowspan="1" colspan="1">SDH, contusion</td>
                          <td align="center" rowspan="1" colspan="1">5</td>
                          <td align="center" rowspan="1" colspan="1">7</td>
                          <td align="center" rowspan="1" colspan="1">Favorable/Rehab</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">23 (Deceased)</td>
                          <td align="center" rowspan="1" colspan="1">Male</td>
                          <td align="center" rowspan="1" colspan="1">White</td>
                          <td align="center" rowspan="1" colspan="1">MCA w/blunt injury</td>
                          <td align="center" rowspan="1" colspan="1">Contusions, DAI, tSAH</td>
                          <td align="center" rowspan="1" colspan="1">3</td>
                          <td align="center" rowspan="1" colspan="1">1</td>
                          <td align="center" rowspan="1" colspan="1">Deceased</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">21</td>
                          <td align="center" rowspan="1" colspan="1">Male</td>
                          <td align="center" rowspan="1" colspan="1">Black</td>
                          <td align="center" rowspan="1" colspan="1">GSW to head w/ penetrating injury</td>
                          <td align="center" rowspan="1" colspan="1">tSAH, Contusion</td>
                          <td align="center" rowspan="1" colspan="1">5</td>
                          <td align="center" rowspan="1" colspan="1">4</td>
                          <td align="center" rowspan="1" colspan="1">Unfavorable</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">63</td>
                          <td align="center" rowspan="1" colspan="1">Male</td>
                          <td align="center" rowspan="1" colspan="1">White</td>
                          <td align="center" rowspan="1" colspan="1">Blunt injury</td>
                          <td align="center" rowspan="1" colspan="1">tSAH, SDH, Contusion</td>
                          <td align="center" rowspan="1" colspan="1">7</td>
                          <td align="center" rowspan="1" colspan="1">1</td>
                          <td align="center" rowspan="1" colspan="1">Deceased</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">21</td>
                          <td align="center" rowspan="1" colspan="1">Male</td>
                          <td align="center" rowspan="1" colspan="1">White</td>
                          <td align="center" rowspan="1" colspan="1">MVA w/blunt injury</td>
                          <td align="center" rowspan="1" colspan="1">Contusion, DAI, tSAH</td>
                          <td align="center" rowspan="1" colspan="1">5</td>
                          <td align="center" rowspan="1" colspan="1">3</td>
                          <td align="center" rowspan="1" colspan="1">Unfavorable</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">45</td>
                          <td align="center" rowspan="1" colspan="1">Male</td>
                          <td align="center" rowspan="1" colspan="1">White</td>
                          <td align="center" rowspan="1" colspan="1">MVC blunt injury</td>
                          <td align="center" rowspan="1" colspan="1">SDH, contusions, tSAH, IVH</td>
                          <td align="center" rowspan="1" colspan="1">8</td>
                          <td align="center" rowspan="1" colspan="1">2</td>
                          <td align="center" rowspan="1" colspan="1">Unfavorable</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">51</td>
                          <td align="center" rowspan="1" colspan="1">Male</td>
                          <td align="center" rowspan="1" colspan="1">White</td>
                          <td align="center" rowspan="1" colspan="1">Blunt injury</td>
                          <td align="center" rowspan="1" colspan="1">EDH, SDH, tSAH</td>
                          <td align="center" rowspan="1" colspan="1">3</td>
                          <td align="center" rowspan="1" colspan="1">7</td>
                          <td align="center" rowspan="1" colspan="1">Favorable/Rehab</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">22</td>
                          <td align="center" rowspan="1" colspan="1">Male</td>
                          <td align="center" rowspan="1" colspan="1">White</td>
                          <td align="center" rowspan="1" colspan="1">MVC w/blunt injury</td>
                          <td align="center" rowspan="1" colspan="1">tSAH, SDH, contusion</td>
                          <td align="center" rowspan="1" colspan="1">3</td>
                          <td align="center" rowspan="1" colspan="1">4</td>
                          <td align="center" rowspan="1" colspan="1">Unfavorable</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="t001fn001">
                      <p><bold>s/p</bold>: status-post; <bold>MCC</bold>: Motor cycle crash; <bold>MVA</bold>: Motor Vehicle Accident; <bold>GSW</bold>: Gunshot wound; <bold>MVC</bold>: Motor Vehicle accident; <bold>MCA</bold>: Motor cycle accident; <bold>IVH</bold>: Intraventricular bleeding; <bold>tSAH</bold>: traumatic Subarachnoid bleeding; <bold>DAI</bold>: Diffuse Axonal Injury; <bold>SDH</bold>: Subdural hematoma; <bold>LSDH</bold>: Left Subdural hematoma; <bold>GCS at resus</bold>: Glasgow Coma Scale at resuscitation; <bold>GOSE</bold>: Glasgow Outcome Scale (Extended).</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <table-wrap id="pone.0210128.t002" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0210128.t002</object-id>
                  <label>Table 2</label>
                  <caption>
                    <title>Summary of control and subjects with TBI.</title>
                  </caption>
                  <alternatives>
                    <graphic id="pone.0210128.t002g" xlink:href="pone.0210128.t002"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" rowspan="1" colspan="1"> </th>
                          <th align="center" rowspan="1" colspan="1">Control</th>
                          <th align="center" rowspan="1" colspan="1">TBI</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Sample Size</bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1">120</td>
                          <td align="center" rowspan="1" colspan="1">21</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Gender</bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1"> </td>
                          <td align="center" rowspan="1" colspan="1"> </td>
                        </tr>
                        <tr>
                          <td align="right" rowspan="1" colspan="1">Male</td>
                          <td align="center" rowspan="1" colspan="1">60</td>
                          <td align="center" rowspan="1" colspan="1">18</td>
                        </tr>
                        <tr>
                          <td align="right" rowspan="1" colspan="1">Female</td>
                          <td align="center" rowspan="1" colspan="1">60</td>
                          <td align="center" rowspan="1" colspan="1">3</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Age Range</bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1">20–70 y/o</td>
                          <td align="center" rowspan="1" colspan="1">21–81 y/o</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Race</bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1"> </td>
                          <td align="center" rowspan="1" colspan="1"> </td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> </td>
                          <td align="center" rowspan="1" colspan="1">White: 28</td>
                          <td align="center" rowspan="1" colspan="1">White: 13</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> </td>
                          <td align="center" rowspan="1" colspan="1">Black: 65</td>
                          <td align="center" rowspan="1" colspan="1">Black: 5</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> </td>
                          <td align="center" rowspan="1" colspan="1">Hispanic: 27</td>
                          <td align="center" rowspan="1" colspan="1">Unknown: 2</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>ASC Levels</bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1"> </td>
                          <td align="left" rowspan="1" colspan="1"> </td>
                        </tr>
                        <tr>
                          <td align="right" rowspan="1" colspan="1">Range</td>
                          <td align="center" rowspan="1" colspan="1">105.6–458.3 pg/ml</td>
                          <td align="center" rowspan="1" colspan="1">138.5–1720 pg/ml</td>
                        </tr>
                        <tr>
                          <td align="right" rowspan="1" colspan="1">Mean</td>
                          <td align="center" rowspan="1" colspan="1">236.6 pg/ml</td>
                          <td align="center" rowspan="1" colspan="1">629 pg/ml</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Caspase-1 Levels</bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1"> </td>
                          <td align="center" rowspan="1" colspan="1"> </td>
                        </tr>
                        <tr>
                          <td align="right" rowspan="1" colspan="1">Range</td>
                          <td align="center" rowspan="1" colspan="1">0.952–2.703 pg/ml</td>
                          <td align="center" rowspan="1" colspan="1">0.918–20.55 pg/ml</td>
                        </tr>
                        <tr>
                          <td align="right" rowspan="1" colspan="1">a</td>
                          <td align="center" rowspan="1" colspan="1">1.436 pg/ml</td>
                          <td align="center" rowspan="1" colspan="1">4.540 pg/ml</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>IL-18 Levels</bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1"> </td>
                          <td align="center" rowspan="1" colspan="1"> </td>
                        </tr>
                        <tr>
                          <td align="right" rowspan="1" colspan="1">Range</td>
                          <td align="center" rowspan="1" colspan="1">40.5–422.7 pg/ml</td>
                          <td align="center" rowspan="1" colspan="1">43.72–587.7 pg/ml</td>
                        </tr>
                        <tr>
                          <td align="right" rowspan="1" colspan="1">Mean</td>
                          <td align="center" rowspan="1" colspan="1">213.5 pg/ml</td>
                          <td align="center" rowspan="1" colspan="1">218.625 pg/ml</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>IL-1beta Levels</bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1"> </td>
                          <td align="center" rowspan="1" colspan="1"> </td>
                        </tr>
                        <tr>
                          <td align="right" rowspan="1" colspan="1">Range</td>
                          <td align="center" rowspan="1" colspan="1">0.413–3.276 pg/ml</td>
                          <td align="center" rowspan="1" colspan="1">0.4–4.674 pg/ml</td>
                        </tr>
                        <tr>
                          <td align="right" rowspan="1" colspan="1">Mean</td>
                          <td align="center" rowspan="1" colspan="1">1.214 pg/ml</td>
                          <td align="center" rowspan="1" colspan="1">1.0618 pg/ml</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="t002fn001">
                      <p><bold>y/o</bold>: years old.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="sec007">
                <title>Simple Plex Assay</title>
                <p>Analysis of inflammasome protein concentration in serum and CSF samples were performed using the Ella System (Protein System) as described in [<xref rid="pone.0210128.ref022" ref-type="bibr">22</xref>, <xref rid="pone.0210128.ref023" ref-type="bibr">23</xref>].</p>
              </sec>
              <sec id="sec008">
                <title>Biomarker analyses</title>
                <p>Data obtained by the Simple Plex assay were analyzed with Prism 7 software (GraphPad). Analyses were carried after removing outliers, and the area under the ROC curve and the 95% confidence interval (CI) were determined. The p-value of significance used was &lt;0.05. Sensitivity and specificity of each biomarker was obtained for a range of different cut-off points. Samples that resulted in values outside the level of detection of the assay were not included in the analyses [<xref rid="pone.0210128.ref022" ref-type="bibr">22</xref>, <xref rid="pone.0210128.ref023" ref-type="bibr">23</xref>]. Multiple group comparisons were carried out using a Kruskal-Wallis test ANOVA followed by Dunn’s multiple comparisons test. Paired comparisons were performed using a two-tailed t-test. Normality was evaluated using the D'Agostino and Pearson normality test. Difference in sample size throughout the study is due to the removal of outliers and because the protein concentration of some samples was out of the range of detection of the assay for some of the analytes and was not evaluated. The box plot shows the 5<sup>th</sup> and 95<sup>th</sup> percentiles, and the line inside the box represents the median.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="sec009">
              <title>Results</title>
              <sec id="sec010">
                <title>ASC and caspase-1 are elevated in the serum of patients after TBI</title>
                <p>We analyzed serum samples (<bold><xref ref-type="supplementary-material" rid="pone.0210128.s001">S1 Table</xref></bold>) from TBI patients and compared them to serum from healthy/control individuals using a Simple Plex assay (Protein Simple) for the protein expression levels of ASC (<bold><xref ref-type="fig" rid="pone.0210128.g001">Fig 1A</xref></bold>), caspase-1 (<bold><xref ref-type="fig" rid="pone.0210128.g001">Fig 1B</xref>)</bold>, IL-18 (<bold><xref ref-type="fig" rid="pone.0210128.g001">Fig 1C</xref>)</bold> and IL-1β (<bold><xref ref-type="fig" rid="pone.0210128.g001">Fig 1D</xref></bold>). Samples were collected three times a day for five days. Data shown corresponds to the 1<sup>st</sup>, 2<sup>nd</sup> 4<sup>th</sup> and 6<sup>th</sup> collection. We determined that the protein levels of ASC were higher in TBI samples (1<sup>st</sup> collection: 693.5+/-108.5 pg/ml, 2<sup>nd</sup>: 562.6+/-84.51 pg/ml, 4<sup>th</sup>: 601.7+/-64.4 pg/ml, 6<sup>th</sup>: 658.2+/-79.69 pg/ml) when compared to samples from subjects without TBI (control, 236.6+/-7.758 pg/ml) (<bold><xref ref-type="fig" rid="pone.0210128.g001">Fig 1A</xref></bold>). Thus, indicating that inflammasome proteins are elevated in serum after TBI.</p>
                <fig id="pone.0210128.g001" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0210128.g001</object-id>
                  <label>Fig 1</label>
                  <caption>
                    <title>Inflammasome proteins are elevated in the serum of TBI patients.</title>
                    <p>Protein levels in pg/ml of ASC (<bold>A</bold>), caspase-1 (B), IL-18 (C) and IL-1β (D) in serum samples from patients with TBI and healthy donors (controls). ASC: N = 120 control, 20 TBI. Caspase-1: N = 11 control, 19 TBI. IL-18: N = 120 control, 21 TBI. IL-1β: N = 25 control, 10 TBI. Box and whiskers are shown for the 5<sup>th</sup> and 95<sup>th</sup> percentile. * p &lt; 0.05.</p>
                  </caption>
                  <graphic xlink:href="pone.0210128.g001"/>
                </fig>
              </sec>
              <sec id="sec011">
                <title>ASC and Caspase-1 are promising serum biomarkers of TBI</title>
                <p>To determine if these inflammasome signaling proteins are reliable biomarkers for TBI in serum, we determined the area under the curve (AUC) for caspase-1 (<bold><xref ref-type="fig" rid="pone.0210128.g002">Fig 2A</xref></bold>), ASC (<bold><xref ref-type="fig" rid="pone.0210128.g002">Fig 2B</xref></bold>), IL-1β (<bold><xref ref-type="fig" rid="pone.0210128.g002">Fig 2C</xref></bold>) and IL-18 (<bold><xref ref-type="fig" rid="pone.0210128.g002">Fig 2D</xref></bold>). AUC values were highest for caspase-1 and ASC (<bold><xref ref-type="fig" rid="pone.0210128.g002">Fig 2</xref></bold>) with 0.93 (4<sup>th</sup> collection) and 0.90 (6<sup>th</sup> collection), respectively (<bold><xref rid="pone.0210128.t003" ref-type="table">Table 3</xref></bold>).</p>
                <fig id="pone.0210128.g002" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0210128.g002</object-id>
                  <label>Fig 2</label>
                  <caption>
                    <p>ROC curves for caspase-1 (<bold>A</bold>), ASC (<bold>B</bold>), IL-1β (<bold>C</bold>) and IL-18 (<bold>D</bold>) from serum samples of TBI patients and healthy donors.</p>
                  </caption>
                  <graphic xlink:href="pone.0210128.g002"/>
                </fig>
                <table-wrap id="pone.0210128.t003" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0210128.t003</object-id>
                  <label>Table 3</label>
                  <caption>
                    <title>ROC analysis results for inflammasome signaling proteins in serum including area, standard error (STD. ERROR), 95% confidence interval (CI) and p-value for collections 1<sup>st</sup>, 2<sup>nd</sup>, 4<sup>th</sup> and 6<sup>th</sup>.</title>
                  </caption>
                  <alternatives>
                    <graphic id="pone.0210128.t003g" xlink:href="pone.0210128.t003"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" rowspan="1" colspan="1">Caspase-1 Serum</th>
                          <th align="center" rowspan="1" colspan="1">AREA</th>
                          <th align="center" rowspan="1" colspan="1">STD. ERROR</th>
                          <th align="center" rowspan="1" colspan="1">95% C.I.</th>
                          <th align="center" rowspan="1" colspan="1">P VALUE</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">1<sup>st</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">0.78</td>
                          <td align="center" rowspan="1" colspan="1">0.08772</td>
                          <td align="center" rowspan="1" colspan="1">0.6058 to 0.9497</td>
                          <td align="center" rowspan="1" colspan="1">0.01</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">2<sup>nd</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">0.83</td>
                          <td align="center" rowspan="1" colspan="1">0.0479</td>
                          <td align="center" rowspan="1" colspan="1">0.8395 to 1.027</td>
                          <td align="center" rowspan="1" colspan="1">0.005</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">4<sup>th</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">0.93</td>
                          <td align="center" rowspan="1" colspan="1">0.1407</td>
                          <td align="center" rowspan="1" colspan="1">0.8353 to 0.8869</td>
                          <td align="center" rowspan="1" colspan="1">0.0002</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">6<sup>th</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">0.91</td>
                          <td align="center" rowspan="1" colspan="1">0.06065</td>
                          <td align="center" rowspan="1" colspan="1">0.7888 to 1.027</td>
                          <td align="center" rowspan="1" colspan="1">0.001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>ASC Serum</bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">1<sup>st</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">0.80</td>
                          <td align="center" rowspan="1" colspan="1">0.06472</td>
                          <td align="center" rowspan="1" colspan="1">0.6762 to 0.9299</td>
                          <td align="center" rowspan="1" colspan="1">&lt;0.0001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">2<sup>nd</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">0.84</td>
                          <td align="center" rowspan="1" colspan="1">0.05026</td>
                          <td align="center" rowspan="1" colspan="1">0.7425 to 0.9395</td>
                          <td align="center" rowspan="1" colspan="1">&lt;0.0001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">4<sup>th</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">0.89</td>
                          <td align="center" rowspan="1" colspan="1">0.04898</td>
                          <td align="center" rowspan="1" colspan="1">0.7931 to 0.9851</td>
                          <td align="center" rowspan="1" colspan="1">&lt;0.0001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">6<sup>th</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">0.90</td>
                          <td align="center" rowspan="1" colspan="1">0.0697</td>
                          <td align="center" rowspan="1" colspan="1">0.759 to 1.032</td>
                          <td align="center" rowspan="1" colspan="1">&lt;0.0001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>IL-1beta Serum</bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">1<sup>st</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">0.7</td>
                          <td align="center" rowspan="1" colspan="1">0.0965</td>
                          <td align="center" rowspan="1" colspan="1">0.5109 to 0.8891</td>
                          <td align="center" rowspan="1" colspan="1">0.0759</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">2<sup>nd</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">0.64</td>
                          <td align="center" rowspan="1" colspan="1">0.1182</td>
                          <td align="center" rowspan="1" colspan="1">0.4085 to 0.8719</td>
                          <td align="center" rowspan="1" colspan="1">0.2304</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">4<sup>th</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">0.6234</td>
                          <td align="center" rowspan="1" colspan="1">0.09765</td>
                          <td align="center" rowspan="1" colspan="1">0.432 to 0.8148</td>
                          <td align="center" rowspan="1" colspan="1">0.2582</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">6<sup>th</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">0.6984</td>
                          <td align="center" rowspan="1" colspan="1">0.1162</td>
                          <td align="center" rowspan="1" colspan="1">0.4707 to 0.9261</td>
                          <td align="center" rowspan="1" colspan="1">0.1448</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>IL-18 Serum</bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">1<sup>st</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">0.61</td>
                          <td align="center" rowspan="1" colspan="1">0.07475</td>
                          <td align="center" rowspan="1" colspan="1">0.4593 to 0.7524</td>
                          <td align="center" rowspan="1" colspan="1">0.1227</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">2<sup>nd</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">0.55</td>
                          <td align="center" rowspan="1" colspan="1">0.07064</td>
                          <td align="center" rowspan="1" colspan="1">0.4082 to 0.6851</td>
                          <td align="center" rowspan="1" colspan="1">0.4966</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">4<sup>th</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">0.51</td>
                          <td align="center" rowspan="1" colspan="1">0.0713</td>
                          <td align="center" rowspan="1" colspan="1">0.372 to 0.6515</td>
                          <td align="center" rowspan="1" colspan="1">0.8666</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">6<sup>th</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">0.55</td>
                          <td align="center" rowspan="1" colspan="1">0.1015</td>
                          <td align="center" rowspan="1" colspan="1">0.3532 to 0.7509</td>
                          <td align="center" rowspan="1" colspan="1">0.5387</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                </table-wrap>
                <p>Furthermore, the cut-off point for caspase-1 was 1.943 pg/ml with 94% sensitivity and 89% specificity (<bold><xref rid="pone.0210128.t004" ref-type="table">Table 4</xref></bold>). For ASC, the cut-off point was 451.3 pg/ml with 85% sensitivity and 99% specificity (<bold><xref rid="pone.0210128.t004" ref-type="table">Table 4</xref></bold>); whereas values for caspase-1 showed 100% sensitivity and the cut-off point was 1.679 pg/ml with 77.78% specificity. For ASC, the cut-off point was 153.4 pg/ml and a 19% specificity. In the case of caspase-1, for 100% specificity, the cut-off point was 2.717 pg/ml with 78% sensitivity. For ASC with 100% specificity, the cut-off point was 462.4 pg/ml with 85% sensitivity. Thus, these findings indicate that caspase-1 and ASC are reliable serum biomarkers for TBI.</p>
                <table-wrap id="pone.0210128.t004" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0210128.t004</object-id>
                  <label>Table 4</label>
                  <caption>
                    <title>ROC analysis results for caspase-1 and ASC in serum including cut-off point in pg/ml, sensitivity and specificity, as well as positive and negative likelihood ratios (LR+/LR-).</title>
                  </caption>
                  <alternatives>
                    <graphic id="pone.0210128.t004g" xlink:href="pone.0210128.t004"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" rowspan="1" colspan="1">Caspase-1 Serum</th>
                          <th align="center" rowspan="1" colspan="1">Cut-off point (pg/ml)</th>
                          <th align="center" rowspan="1" colspan="1">Sensitivity (%)</th>
                          <th align="center" rowspan="1" colspan="1">Specificity (%)</th>
                          <th align="center" rowspan="1" colspan="1">LR +</th>
                          <th align="center" rowspan="1" colspan="1">LR -</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">1<sup>st</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">&gt; 1.439</td>
                          <td align="center" rowspan="1" colspan="1">83</td>
                          <td align="center" rowspan="1" colspan="1">67</td>
                          <td align="center" rowspan="1" colspan="1">2.50</td>
                          <td align="center" rowspan="1" colspan="1">0.25</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">2<sup>nd</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">&gt; 1.531</td>
                          <td align="center" rowspan="1" colspan="1">94</td>
                          <td align="center" rowspan="1" colspan="1">78</td>
                          <td align="center" rowspan="1" colspan="1">4.24</td>
                          <td align="center" rowspan="1" colspan="1">0.08</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">4<sup>th</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">&gt; 1.943</td>
                          <td align="center" rowspan="1" colspan="1">94</td>
                          <td align="center" rowspan="1" colspan="1">89</td>
                          <td align="center" rowspan="1" colspan="1">8.50</td>
                          <td align="center" rowspan="1" colspan="1"><italic>0</italic>.<italic>06</italic></td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">6<sup>th</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">&gt; 1.947</td>
                          <td align="center" rowspan="1" colspan="1">85</td>
                          <td align="center" rowspan="1" colspan="1">89</td>
                          <td align="center" rowspan="1" colspan="1">7.62</td>
                          <td align="center" rowspan="1" colspan="1">0.17</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>ASC Serum</bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">1<sup>st</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">&gt; 210</td>
                          <td align="center" rowspan="1" colspan="1">85</td>
                          <td align="center" rowspan="1" colspan="1">43</td>
                          <td align="center" rowspan="1" colspan="1">1.50</td>
                          <td align="center" rowspan="1" colspan="1">0.35</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">2<sup>nd</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">&gt; 275</td>
                          <td align="center" rowspan="1" colspan="1">81</td>
                          <td align="center" rowspan="1" colspan="1">72</td>
                          <td align="center" rowspan="1" colspan="1">2.91</td>
                          <td align="center" rowspan="1" colspan="1">0.26</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">4<sup>th</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">&gt; 339.4</td>
                          <td align="center" rowspan="1" colspan="1">80</td>
                          <td align="center" rowspan="1" colspan="1">88</td>
                          <td align="center" rowspan="1" colspan="1">6.57</td>
                          <td align="center" rowspan="1" colspan="1">0.23</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">6<sup>th</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">&gt; 451.3</td>
                          <td align="center" rowspan="1" colspan="1">85</td>
                          <td align="center" rowspan="1" colspan="1">99</td>
                          <td align="center" rowspan="1" colspan="1">97.26</td>
                          <td align="center" rowspan="1" colspan="1">0.16</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                </table-wrap>
              </sec>
              <sec id="sec012">
                <title>ASC and IL-18 are elevated in the CSF of patients after TBI</title>
                <p>We then analyzed CSF samples (<bold><xref ref-type="supplementary-material" rid="pone.0210128.s002">S2 Table</xref></bold>) from TBI patients and compared them to CSF from no-TBI control individuals for the protein expression of ASC (<xref ref-type="fig" rid="pone.0210128.g003">Fig 3A</xref>) and IL-18 (<xref ref-type="fig" rid="pone.0210128.g003">Fig 3B</xref>). The protein levels of ASC and IL-18 were higher in TBI samples (ASC 1<sup>st</sup>: 473.8+/-129.4 pg/ml, 2<sup>nd</sup>: 132.8+/-24.45 pg/ml, 4<sup>th</sup>: 362.1+/-106.3 pg/ml, 6<sup>th</sup>: 325.4+/-124.4 pg/ml, IL-18: 1<sup>st</sup>: 9.164+/-2.169, 2<sup>nd</sup>: 4.626+/-0.7595 pg/ml, 4<sup>th</sup>: 4.169+/-0.7801 pg/ml) when compared to control samples (ASC: 48.52+/-2.259 pg/ml, IL-18: 2.246+/-0.1971). Moreover, the protein concentration of caspase-1 and IL-1β in the CSF was below the level of detection of the assay. Thus, we were unable to carry out any statistical analysis for these two proteins in the present study. These findings are consistent with previous reports indicating a role for the inflammasome in the pathology of TBI [<xref rid="pone.0210128.ref020" ref-type="bibr">20</xref>, <xref rid="pone.0210128.ref024" ref-type="bibr">24</xref>].</p>
                <fig id="pone.0210128.g003" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0210128.g003</object-id>
                  <label>Fig 3</label>
                  <caption>
                    <title>Inflammasome proteins are elevated in the CSF of TBI patients.</title>
                    <p>Protein levels in pg/ml of ASC (<bold>A</bold>) and IL-18 (<bold>B</bold>) in CSF samples from patients with TBI and healthy donors (controls). ASC: N = 21 control, 15 TBI. IL-18: N = 24 control, 16 TBI. Box and whiskers are shown for the 5<sup>th</sup> and 95<sup>th</sup> percentile. * p &lt; 0.05.</p>
                  </caption>
                  <graphic xlink:href="pone.0210128.g003"/>
                </fig>
              </sec>
              <sec id="sec013">
                <title>ASC and IL-18 are reliable CSF biomarkers of TBI</title>
                <p>Next, we determined whether ASC and IL-18 are reliable biomarkers in CSF for TBI. The area under the curve (AUC) for ASC (<bold><xref ref-type="fig" rid="pone.0210128.g004">Fig 4A</xref></bold>) was 1.0 for the 6<sup>th</sup> collection (<bold><xref rid="pone.0210128.t005" ref-type="table">Table 5</xref></bold>), and for IL-18 (<bold><xref ref-type="fig" rid="pone.0210128.g004">Fig 4B</xref></bold>) the AUC was 0.84 for the 1<sup>st</sup> collection (<bold><xref rid="pone.0210128.t005" ref-type="table">Table 5</xref></bold>), indicating that ASC is a more reliable biomarker than IL-18 in CSF after TBI.</p>
                <fig id="pone.0210128.g004" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0210128.g004</object-id>
                  <label>Fig 4</label>
                  <caption>
                    <p>ROC curves for ASC (<bold>A</bold>) and IL-18 (<bold>B</bold>) from CSF samples of TBI patients and healthy donors.</p>
                  </caption>
                  <graphic xlink:href="pone.0210128.g004"/>
                </fig>
                <table-wrap id="pone.0210128.t005" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0210128.t005</object-id>
                  <label>Table 5</label>
                  <caption>
                    <title>ROC analysis results for ASC and IL-18 in CSF including area, standard error (STD. ERROR), 95% confidence interval (CI) and p-value for collections 1<sup>st</sup>, 2<sup>nd</sup>, 4<sup>th</sup> and 6<sup>th</sup>.</title>
                  </caption>
                  <alternatives>
                    <graphic id="pone.0210128.t005g" xlink:href="pone.0210128.t005"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" rowspan="1" colspan="1">ASC CSF</th>
                          <th align="center" rowspan="1" colspan="1">AREA</th>
                          <th align="center" rowspan="1" colspan="1">STD. ERROR</th>
                          <th align="center" rowspan="1" colspan="1">95% C.I.</th>
                          <th align="center" rowspan="1" colspan="1">P VALUE</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">1<sup>st</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">0.981</td>
                          <td align="center" rowspan="1" colspan="1">0.0195</td>
                          <td align="center" rowspan="1" colspan="1">0.9427 to 1.019</td>
                          <td align="center" rowspan="1" colspan="1">&lt;0.0001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">2<sup>nd</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">0.8418</td>
                          <td align="center" rowspan="1" colspan="1">0.07661</td>
                          <td align="center" rowspan="1" colspan="1">0.6917 to 0.992</td>
                          <td align="center" rowspan="1" colspan="1">0.0021</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">4<sup>th</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">0.898</td>
                          <td align="center" rowspan="1" colspan="1">0.07262</td>
                          <td align="center" rowspan="1" colspan="1">0.7556 to 1.04</td>
                          <td align="center" rowspan="1" colspan="1">0.0003</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">6<sup>th</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">1</td>
                          <td align="center" rowspan="1" colspan="1">0</td>
                          <td align="center" rowspan="1" colspan="1">1 to 1</td>
                          <td align="center" rowspan="1" colspan="1">0.0001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>IL-18 CSF</bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">1<sup>st</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">0.8404</td>
                          <td align="center" rowspan="1" colspan="1">0.0731</td>
                          <td align="center" rowspan="1" colspan="1">0.6971 to 0.9836</td>
                          <td align="center" rowspan="1" colspan="1">0.0008</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">2<sup>nd</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">0.8195</td>
                          <td align="center" rowspan="1" colspan="1">0.07969</td>
                          <td align="center" rowspan="1" colspan="1">0.6634 to 0.9757</td>
                          <td align="center" rowspan="1" colspan="1">0.002</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">4<sup>th</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">0.7632</td>
                          <td align="center" rowspan="1" colspan="1">0.1061</td>
                          <td align="center" rowspan="1" colspan="1">0.552 to 0.9711</td>
                          <td align="center" rowspan="1" colspan="1">0.9711</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">6<sup>th</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">0.5132</td>
                          <td align="center" rowspan="1" colspan="1">0.1344</td>
                          <td align="center" rowspan="1" colspan="1">0.2498 to 0.7765</td>
                          <td align="center" rowspan="1" colspan="1">0.9154</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                </table-wrap>
                <p>The cut-off point for ASC was 74.33 pg/ml with 100% sensitivity and 100% specificity (<bold><xref rid="pone.0210128.t006" ref-type="table">Table 6</xref></bold>). For IL-18, the cut-off point was 2.722 pg/ml with 80% sensitivity and 68% specificity (<bold><xref rid="pone.0210128.t006" ref-type="table">Table 6</xref></bold>). In the case of IL-18, for 100% specificity, the cut-off point was 3.879 pg/ml with 60% sensitivity, and for 100% sensitivity, the cut-off point was 1.358 pg/ml with 16% specificity. Thus, these findings indicate that ASC and IL-18 are promising biomarkers in CSF for TBI.</p>
                <table-wrap id="pone.0210128.t006" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0210128.t006</object-id>
                  <label>Table 6</label>
                  <caption>
                    <title>ROC analysis results for ASC and IL-18 in CSF including cut-off point in pg/ml, sensitivity and specificity, as well as positive and negative likelihood ratios (LR+/LR-).</title>
                  </caption>
                  <alternatives>
                    <graphic id="pone.0210128.t006g" xlink:href="pone.0210128.t006"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" rowspan="1" colspan="1">ASC CSF</th>
                          <th align="center" rowspan="1" colspan="1">Cut-off point (pg/ml)</th>
                          <th align="center" rowspan="1" colspan="1">Sensitivity (%)</th>
                          <th align="center" rowspan="1" colspan="1">Specificity (%)</th>
                          <th align="center" rowspan="1" colspan="1">LR +</th>
                          <th align="center" rowspan="1" colspan="1">LR -</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">1<sup>st</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">&gt; 55.11</td>
                          <td align="center" rowspan="1" colspan="1">100</td>
                          <td align="center" rowspan="1" colspan="1">85.71</td>
                          <td align="center" rowspan="1" colspan="1">7</td>
                          <td align="center" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">2<sup>nd</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">&gt; 50.25</td>
                          <td align="center" rowspan="1" colspan="1">78.57</td>
                          <td align="center" rowspan="1" colspan="1">64.29</td>
                          <td align="center" rowspan="1" colspan="1">2.20</td>
                          <td align="center" rowspan="1" colspan="1">0.33</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">4<sup>th</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">&gt; 64.58</td>
                          <td align="center" rowspan="1" colspan="1">85.71</td>
                          <td align="center" rowspan="1" colspan="1">92.86</td>
                          <td align="center" rowspan="1" colspan="1">12</td>
                          <td align="center" rowspan="1" colspan="1">0.15</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">6<sup>th</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">&gt; 74.33</td>
                          <td align="center" rowspan="1" colspan="1">100</td>
                          <td align="center" rowspan="1" colspan="1">100</td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1">0</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>IL-18 CSF</bold>
                          </td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">1<sup>st</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">&gt; 2.722</td>
                          <td align="center" rowspan="1" colspan="1">80</td>
                          <td align="center" rowspan="1" colspan="1">68.42</td>
                          <td align="center" rowspan="1" colspan="1">2.53</td>
                          <td align="center" rowspan="1" colspan="1">0.29</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">2<sup>nd</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">&gt; 2.221</td>
                          <td align="center" rowspan="1" colspan="1">85.71</td>
                          <td align="center" rowspan="1" colspan="1">57.89</td>
                          <td align="center" rowspan="1" colspan="1">2.04</td>
                          <td align="center" rowspan="1" colspan="1">0.25</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">4<sup>th</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">&gt; 3.055</td>
                          <td align="center" rowspan="1" colspan="1">70</td>
                          <td align="center" rowspan="1" colspan="1">84.21</td>
                          <td align="center" rowspan="1" colspan="1">4.43</td>
                          <td align="center" rowspan="1" colspan="1">0.36</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">6<sup>th</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">&gt; 1.707</td>
                          <td align="center" rowspan="1" colspan="1">75</td>
                          <td align="center" rowspan="1" colspan="1">36.84</td>
                          <td align="center" rowspan="1" colspan="1">1.19</td>
                          <td align="center" rowspan="1" colspan="1">0.68</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                </table-wrap>
              </sec>
              <sec id="sec014">
                <title>ASC is elevated in the serum of patients with unfavorable outcomes after TBI</title>
                <p>We then separated the TBI patients according to their clinical outcomes (<bold><xref ref-type="supplementary-material" rid="pone.0210128.s003">S3 Table</xref></bold>); either favorable or unfavorable outcomes based on the Glasgow Outcome Scale-Extended (GOSE) in which patients with a score of 6 to 8 were considered to have favorable outcomes and those with a score of 1 to 4 were considered to have unfavorable outcomes (<bold><xref rid="pone.0210128.t001" ref-type="table">Table 1</xref></bold>). We found that the protein level of ASC was higher in the serum of TBI patients with unfavorable outcomes (2<sup>nd</sup>: 652.9+/-100.9pg/ml, 4<sup>th</sup>: 719.2+/-68.14 pg/ml) when compared to the samples obtained from patients with favorable outcomes (2<sup>nd</sup>: 273.7+/-19.41 pg/ml, 4<sup>th</sup>: 327.6+/-53.84 pg/ml) (<bold><xref ref-type="fig" rid="pone.0210128.g005">Fig 5B</xref></bold>), whereas the caspase-1 (<bold><xref ref-type="fig" rid="pone.0210128.g005">Fig 5A</xref></bold>) and IL-18 (<bold><xref ref-type="fig" rid="pone.0210128.g005">Fig 5C</xref></bold>) levels were not statistically different between the two groups.</p>
                <fig id="pone.0210128.g005" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0210128.g005</object-id>
                  <label>Fig 5</label>
                  <caption>
                    <title>Inflammasome proteins as predictive biomarkers of TBI.</title>
                    <p>Protein levels in pg/ml of caspase-1 (<bold>A</bold>), ASC (<bold>B</bold>), and IL-18 (<bold>C</bold>) in serum samples from patients with TBI. Groups were divided into favorable and unfavorable outcomes based on the GOSE. p-value of significance is shown above each box plot. Box and whiskers are shown for the 5<sup>th</sup> and 95<sup>th</sup> percentile. Caspase-1: N = 4 favorable and 16 unfavorable ASC: N = 5 favorable and 16 unfavorable; and IL-18: N = 5 favorable and 16 unfavorable.</p>
                  </caption>
                  <graphic xlink:href="pone.0210128.g005"/>
                </fig>
              </sec>
              <sec id="sec015">
                <title>ASC is a promising predictive biomarker of TBI in serum</title>
                <p>To determine if ASC in serum can be used as predictive biomarkers of TBI, we determined the AUC for ASC at the 2<sup>nd</sup> (<bold><xref ref-type="fig" rid="pone.0210128.g006">Fig 6A</xref></bold>) and 4<sup>th</sup> collection (<bold><xref ref-type="fig" rid="pone.0210128.g006">Fig 6B</xref></bold>). The AUC for ASC was 0.9167 in the 4<sup>th</sup> collection with a CI between 0.7914 and 1.042 (<bold><xref rid="pone.0210128.t007" ref-type="table">Table 7</xref></bold>). Furthermore, the cut-off point was 547.6 pg/ml with 86% sensitivity and 100% specificity (<bold><xref rid="pone.0210128.t008" ref-type="table">Table 8</xref>)</bold>. Thus, these findings indicate that ASC is an excellent predictive biomarker of TBI.</p>
                <fig id="pone.0210128.g006" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0210128.g006</object-id>
                  <label>Fig 6</label>
                  <caption>
                    <title>ROC curves for ASC outcomes (Favorable vs. Unfavorable) for the 2<sup>nd</sup> and 4<sup>th</sup> collection.</title>
                  </caption>
                  <graphic xlink:href="pone.0210128.g006"/>
                </fig>
                <table-wrap id="pone.0210128.t007" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0210128.t007</object-id>
                  <label>Table 7</label>
                  <caption>
                    <title>ROC analysis results for ASC in serum for Favorable vs Unfavorable outcomes, including area, standard error (STD. ERROR), 95% confidence interval (CI) and p-value for collections 1<sup>st</sup>, 2<sup>nd</sup> and 4<sup>th</sup>.</title>
                  </caption>
                  <alternatives>
                    <graphic id="pone.0210128.t007g" xlink:href="pone.0210128.t007"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" rowspan="1" colspan="1">ASC Serum (GOSE)</th>
                          <th align="center" rowspan="1" colspan="1">AREA</th>
                          <th align="center" rowspan="1" colspan="1">STD. ERROR</th>
                          <th align="center" rowspan="1" colspan="1">95% C.I.</th>
                          <th align="center" rowspan="1" colspan="1">P VALUE</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">1<sup>st</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">0.7625</td>
                          <td align="center" rowspan="1" colspan="1">0.1133</td>
                          <td align="center" rowspan="1" colspan="1">0.544 to 0.9846</td>
                          <td align="center" rowspan="1" colspan="1">0.0829</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">2<sup>nd</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">0.85</td>
                          <td align="center" rowspan="1" colspan="1">0.08355</td>
                          <td align="center" rowspan="1" colspan="1">0.6862 to 1.014</td>
                          <td align="center" rowspan="1" colspan="1">0.0208</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">4<sup>th</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">0.9167</td>
                          <td align="center" rowspan="1" colspan="1">0.06391</td>
                          <td align="center" rowspan="1" colspan="1">0.7914 to 1.042</td>
                          <td align="center" rowspan="1" colspan="1">0.0039</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                </table-wrap>
                <table-wrap id="pone.0210128.t008" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0210128.t008</object-id>
                  <label>Table 8</label>
                  <caption>
                    <title>ROC analysis results for ASC in serum for Favorable vs Unfavorable outcomes, including cut-off point in pg/ml, sensitivity and specificity, as well as positive and negative likelihood ratios (LR+/LR-) for collections 1<sup>st</sup>, 2<sup>nd</sup> and 4<sup>th</sup>.</title>
                  </caption>
                  <alternatives>
                    <graphic id="pone.0210128.t008g" xlink:href="pone.0210128.t008"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" rowspan="1" colspan="1">ASC Serum (GOSE)</th>
                          <th align="center" rowspan="1" colspan="1">CUT-OFF POINT (pg/ml)</th>
                          <th align="center" rowspan="1" colspan="1">SENSITIVITY (%)</th>
                          <th align="center" rowspan="1" colspan="1">SPECIFICITY (%)</th>
                          <th align="center" rowspan="1" colspan="1">LR +</th>
                          <th align="center" rowspan="1" colspan="1">LR -</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">1<sup>st</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">&gt; 353.7</td>
                          <td align="center" rowspan="1" colspan="1">75</td>
                          <td align="center" rowspan="1" colspan="1">80</td>
                          <td align="center" rowspan="1" colspan="1">3.75</td>
                          <td align="center" rowspan="1" colspan="1">0.31</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">2<sup>nd</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">&gt; 311.2</td>
                          <td align="center" rowspan="1" colspan="1">81.25</td>
                          <td align="center" rowspan="1" colspan="1">80</td>
                          <td align="center" rowspan="1" colspan="1">4.06</td>
                          <td align="center" rowspan="1" colspan="1">0.23</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">4<sup>th</sup> Collection</td>
                          <td align="center" rowspan="1" colspan="1">&gt; 547.6</td>
                          <td align="center" rowspan="1" colspan="1">85.71</td>
                          <td align="center" rowspan="1" colspan="1">100</td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1">0.14</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                </table-wrap>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="sec016">
              <title>Discussion</title>
              <p>TBI affects approximately 10 million people worldwide and has become a major cause of death and disability [<xref rid="pone.0210128.ref025" ref-type="bibr">25</xref>]. TBI severity is categorized as mild, moderate or severe. Signs and symptoms of TBI may include loss of consciousness, amnesia, nausea, dizziness, headaches, cognitive decline, structural brain damage and presence of other neurological symptoms [<xref rid="pone.0210128.ref026" ref-type="bibr">26</xref>]. The level of consciousness after TBI is often used to determine the severity of trauma in the Glasgow Coma Scale (GCS) score. This score is combined with brain radiographic imaging, other neurological findings and fluid biomarkers to assess the clinical status of the patient[<xref rid="pone.0210128.ref027" ref-type="bibr">27</xref>]. Fluid biomarkers can be obtained from CSF, serum or plasma. Potential biomarkers for the care of patients with TBI include total tau (T-Tau), amyloid-β (Aβ), UCH-L1, NSE, spectrin-α chain, S100B and GFAP [<xref rid="pone.0210128.ref026" ref-type="bibr">26</xref>]. Although there appears to be a variety of candidate proteins that may be potentially used as biomarkers, many studies have only looked at protein levels across patient cohorts including controls. Many of the studies aiming at identify biomarkers of TBI have failed to use the adequate statistical analyses that are needed to determine the suitability of a protein as a biomarker. These analyses include determination of the AUC, sensitivity, specificity and likelihood ratio as well as positive and negative predictive values [<xref rid="pone.0210128.ref023" ref-type="bibr">23</xref>]. Currently, there is only one approved FDA test for blood-based biomarkers in the United States, involving GFAP and UCH-L1, [<xref rid="pone.0210128.ref028" ref-type="bibr">28</xref>] which was approved this year.</p>
              <p>In the present study, we show that ASC and IL-18 are reliable biomarkers for TBI in CSF with AUC values of 1.0 and 0.84, respectively. Most importantly, since obtaining CSF is a very invasive procedure, our finding that inflammasome proteins are elevated in serum, opens the possibility of using a less invasive test such as a blood test for biomarker analysis. In serum, we found that the AUC values for ASC was 0.90 and for caspase-1, 0.93. Thus, of the inflammasome proteins that we tested in this study, caspase-1 and ASC are the best candidate biomarkers in serum for the care of patients with brain injury. Thus, the development of a clinically validated brain biomarker test involving inflammasome proteins has the potential to alter diagnostic approaches and development of clinical care procedures of TBI subjects.</p>
              <p>The importance of inflammasome regulation in TBI secondary injury processes has been recently reported. The NLRP1 inflammasome plays a significant role in the inflammatory response after TBI[<xref rid="pone.0210128.ref009" ref-type="bibr">9</xref>], and inhibition of NLRP1 signaling by antibody neurtralization results in decreased inflammation and improved histopathology after brain injury [<xref rid="pone.0210128.ref009" ref-type="bibr">9</xref>]. Additionally, the NLRP3 inflammasome is activated after brain injury [<xref rid="pone.0210128.ref029" ref-type="bibr">29</xref>, <xref rid="pone.0210128.ref030" ref-type="bibr">30</xref>], and inhibition of the NLRP3 inflammasome results in decreased inflammation and improved neurological function in a mouse model of brain injury [<xref rid="pone.0210128.ref031" ref-type="bibr">31</xref>, <xref rid="pone.0210128.ref032" ref-type="bibr">32</xref>]. The AIM2 inflammasome has been associated with the inflammasome-mediated cell death mechanism of pyroptosis, thus affecting blood brain barrier permeability after trauma [<xref rid="pone.0210128.ref015" ref-type="bibr">15</xref>, <xref rid="pone.0210128.ref033" ref-type="bibr">33</xref>]. Inflammasome proteins are elevated in the CSF of patients with TBI, and high levels of these proteins correlate with poor outcomes in the chronic stages after injury [<xref rid="pone.0210128.ref024" ref-type="bibr">24</xref>]. Lastly, hyperbaric oxygen therapy, [<xref rid="pone.0210128.ref034" ref-type="bibr">34</xref>] hypothermia, [<xref rid="pone.0210128.ref035" ref-type="bibr">35</xref>] omega-3 fatty acids, [<xref rid="pone.0210128.ref036" ref-type="bibr">36</xref>] resveratrol[<xref rid="pone.0210128.ref037" ref-type="bibr">37</xref>] and propofol [<xref rid="pone.0210128.ref038" ref-type="bibr">38</xref>] provide beneficial effects after TBI by lowering inflammasome activation. Thus, innate immune inflammatory processes regulated by inflammasomes play an integral role in pathological processes following TBI.</p>
              <p>Standards for Reporting Diagnostic accuracy studies (STARD) guidelines were used in this study. However, our study has several limitations. For example, the sample collection time points from patients after trauma was not uniform. As a result, the second collection of samples from patients varied after trauma. In addition, we were unable to collect CSF from all patients, and as a result the number of CSF samples are lower when compared to the number of serum samples. In addition, most samples collected in this study were obtained from subjects with severe TBI. Thus, future studies are needed to evaluate the prognostic potential of these biomarker in patients with mild TBI. Moreover, patients enrolled in this study suffered from isolated head trauma (i.e. gunshot wound) or had polytrauma (i.e. motorvehicle accident). As a result, it is likely that the effects of trauma on serum levels of inflammasome proteins are not entirely related to brain injury but to tissue damage originating in other organs such as lung [<xref rid="pone.0210128.ref019" ref-type="bibr">19</xref>], spleen or liver. Lastly, our study involved Whites and Blacks but did not contain Hispanics or other races in the TBI cohort.</p>
              <p>We have recently shown that inflammasome proteins may be used as biomarkers of multiple sclerosis, stroke and depression [<xref rid="pone.0210128.ref023" ref-type="bibr">23</xref>, <xref rid="pone.0210128.ref039" ref-type="bibr">39</xref>, <xref rid="pone.0210128.ref040" ref-type="bibr">40</xref>]. However, patients in each disease category present different levels of inflammasome proteins and these levels may vary depending on disease severity. Thus, it is likely that these proteins may be used to monitor disease inflammatory progression or severity. The specificity of inflammasome proteins as biomarkers may be altered by changing the cut-off point to reflect a different sensitivity since sensitivity and specificity are inversely correlated such that as specificity increases, sensitivity decreases. In this study, we chose to set cut-off points that provided high sensitivity and the highest possible specificity for all analytes. Therefore, for clinical purposes the sensitivity should be set at the highest level and the specificity may be increased by the addition of other clinical findings such as imaging biomarkers, symptoms or other fluid-based biomarkers.</p>
              <p>In conclusion, in this study we show that the inflammasome protein ASC may be use as a biomarker of TBI in serum and CSF, whereas caspase-1 may be used as a serum biomarker and IL-18 as a biomarker in CSF. In future studies, we will analyze these biomarkers in larger cohorts of patients with more stratified and specific types of brain injury. Importantly, the identification of these proteins as biomarkers is also indicative of their potential as therapeutic targets for the treatment of inflammation after trauma.</p>
            </sec>
            <sec sec-type="supplementary-material" id="sec017">
              <title>Supporting information</title>
              <supplementary-material content-type="local-data" id="pone.0210128.s001">
                <label>S1 Table</label>
                <caption>
                  <title>Raw data used in the analysis of biomarkers in serum samples.</title>
                  <p>(PDF)</p>
                </caption>
                <media xlink:href="pone.0210128.s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0210128.s002">
                <label>S2 Table</label>
                <caption>
                  <title>Raw data used in the analysis of biomarkers in CSF samples.</title>
                  <p>(PDF)</p>
                </caption>
                <media xlink:href="pone.0210128.s002.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="pone.0210128.s003">
                <label>S3 Table</label>
                <caption>
                  <title>Raw data used in the analysis of biomarkers in serum samples for patients with favorable vs unfavorable outcomes.</title>
                  <p>(PDF)</p>
                </caption>
                <media xlink:href="pone.0210128.s003.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <p>This work was supported by a STTR grant (4R42NS086274-012) from the NINDS/NIH to RWK and WDD and by a public grant from Fondo de Investigación Sanitaria (FIS PI16/00737) to JPB.</p>
            </ack>
            <ref-list>
              <title>References</title>
              <ref id="pone.0210128.ref001">
                <label>1</label>
                <mixed-citation publication-type="journal"><name><surname>Yokobori</surname><given-names>S</given-names></name>, <name><surname>Gajavelli</surname><given-names>S</given-names></name>, <name><surname>Mondello</surname><given-names>S</given-names></name>, <name><surname>Mo-Seaney</surname><given-names>J</given-names></name>, <name><surname>Bramlett</surname><given-names>HM</given-names></name>, <name><surname>Dietrich</surname><given-names>WD</given-names></name>, <etal>et al</etal><article-title>Neuroprotective effect of preoperatively induced mild hypothermia as determined by biomarkers and histopathological estimation in a rat subdural hematoma decompression model</article-title>. <source>J Neurosurg</source>. <year>2013</year>;<volume>118</volume>(<issue>2</issue>):<fpage>370</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.3171/2012.10.JNS12725</pub-id>
<?supplied-pmid 23140154?><pub-id pub-id-type="pmid">23140154</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref002">
                <label>2</label>
                <mixed-citation publication-type="journal"><name><surname>Mondello</surname><given-names>S</given-names></name>, <name><surname>Palmio</surname><given-names>J</given-names></name>, <name><surname>Streeter</surname><given-names>J</given-names></name>, <name><surname>Hayes</surname><given-names>RL</given-names></name>, <name><surname>Peltola</surname><given-names>J</given-names></name>, <name><surname>Jeromin</surname><given-names>A</given-names></name>. <article-title>Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) is increased in cerebrospinal fluid and plasma of patients after epileptic seizure</article-title>. <source>BMC Neurol</source>. <year>2012</year>;<volume>12</volume>:<fpage>85</fpage><pub-id pub-id-type="doi">10.1186/1471-2377-12-85</pub-id><?supplied-pmid 22931063?><pub-id pub-id-type="pmid">22931063</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref003">
                <label>3</label>
                <mixed-citation publication-type="journal"><name><surname>Mondello</surname><given-names>S</given-names></name>, <name><surname>Jeromin</surname><given-names>A</given-names></name>, <name><surname>Buki</surname><given-names>A</given-names></name>, <name><surname>Bullock</surname><given-names>R</given-names></name>, <name><surname>Czeiter</surname><given-names>E</given-names></name>, <name><surname>Kovacs</surname><given-names>N</given-names></name>, <etal>et al</etal><article-title>Glial neuronal ratio: a novel index for differentiating injury type in patients with severe traumatic brain injury</article-title>. <source>J Neurotrauma</source>. <year>2012</year>;<volume>29</volume>(<issue>6</issue>):<fpage>1096</fpage>–<lpage>104</lpage>. <pub-id pub-id-type="doi">10.1089/neu.2011.2092</pub-id>
<?supplied-pmid 22165978?><pub-id pub-id-type="pmid">22165978</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref004">
                <label>4</label>
                <mixed-citation publication-type="journal"><name><surname>Strathmann</surname><given-names>FG</given-names></name>, <name><surname>Schulte</surname><given-names>S</given-names></name>, <name><surname>Goerl</surname><given-names>K</given-names></name>, <name><surname>Petron</surname><given-names>DJ</given-names></name>. <article-title>Blood-based biomarkers for traumatic brain injury: evaluation of research approaches, available methods and potential utility from the clinician and clinical laboratory perspectives</article-title>. <source>Clin Biochem</source>. <year>2014</year>;<volume>47</volume>(<issue>10–11</issue>):<fpage>876</fpage>–<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1016/j.clinbiochem.2014.01.028</pub-id> .<?supplied-pmid 24486649?><pub-id pub-id-type="pmid">24486649</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref005">
                <label>5</label>
                <mixed-citation publication-type="journal"><name><surname>Yokobori</surname><given-names>S</given-names></name>, <name><surname>Hosein</surname><given-names>K</given-names></name>, <name><surname>Burks</surname><given-names>S</given-names></name>, <name><surname>Sharma</surname><given-names>I</given-names></name>, <name><surname>Gajavelli</surname><given-names>S</given-names></name>, <name><surname>Bullock</surname><given-names>R</given-names></name>. <article-title>Biomarkers for the clinical differential diagnosis in traumatic brain injury—a systematic review</article-title>. <source>CNS Neurosci Ther</source>. <year>2013</year>;<volume>19</volume>(<issue>8</issue>):<fpage>556</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1111/cns.12127</pub-id> .<?supplied-pmid 23710877?><pub-id pub-id-type="pmid">23710877</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref006">
                <label>6</label>
                <mixed-citation publication-type="journal"><name><surname>Zetterberg</surname><given-names>H</given-names></name>, <name><surname>Smith</surname><given-names>DH</given-names></name>, <name><surname>Blennow</surname><given-names>K</given-names></name>. <article-title>Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood</article-title>. <source>Nat Rev Neurol</source>. <year>2013</year>;<volume>9</volume>(<issue>4</issue>):<fpage>201</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1038/nrneurol.2013.9</pub-id>
<?supplied-pmid 23399646?><pub-id pub-id-type="pmid">23399646</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref007">
                <label>7</label>
                <mixed-citation publication-type="journal"><name><surname>Lagerstedt</surname><given-names>L</given-names></name>, <name><surname>Egea-Guerrero</surname><given-names>JJ</given-names></name>, <name><surname>Bustamante</surname><given-names>A</given-names></name>, <name><surname>Rodriguez-Rodriguez</surname><given-names>A</given-names></name>, <name><surname>El Rahal</surname><given-names>A</given-names></name>, <name><surname>Quintana-Diaz</surname><given-names>M</given-names></name>, <etal>et al</etal><article-title>Combining H-FABP and GFAP increases the capacity to differentiate between CT-positive and CT-negative patients with mild traumatic brain injury</article-title>. <source>PLoS One</source>. <year>2018</year>;<volume>13</volume>(<issue>7</issue>):<fpage>e0200394</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0200394</pub-id><?supplied-pmid 29985933?><pub-id pub-id-type="pmid">29985933</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref008">
                <label>8</label>
                <mixed-citation publication-type="journal"><name><surname>de Rivero Vaccari</surname><given-names>JP</given-names></name>, <name><surname>Lotocki</surname><given-names>G</given-names></name>, <name><surname>Marcillo</surname><given-names>AE</given-names></name>, <name><surname>Dietrich</surname><given-names>WD</given-names></name>, <name><surname>Keane</surname><given-names>RW</given-names></name>. <article-title>A molecular platform in neurons regulates inflammation after spinal cord injury</article-title>. <source>J Neurosci</source>. <year>2008</year>;<volume>28</volume>(<issue>13</issue>):<fpage>3404</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0157-08.2008</pub-id> .<?supplied-pmid 18367607?><pub-id pub-id-type="pmid">18367607</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref009">
                <label>9</label>
                <mixed-citation publication-type="journal"><name><surname>de Rivero Vaccari</surname><given-names>JP</given-names></name>, <name><surname>Lotocki</surname><given-names>G</given-names></name>, <name><surname>Alonso</surname><given-names>OF</given-names></name>, <name><surname>Bramlett</surname><given-names>HM</given-names></name>, <name><surname>Dietrich</surname><given-names>WD</given-names></name>, <name><surname>Keane</surname><given-names>RW</given-names></name>. <article-title>Therapeutic neutralization of the NLRP1 inflammasome reduces the innate immune response and improves histopathology after traumatic brain injury</article-title>. <source>J Cereb Blood Flow Metab</source>. <year>2009</year>;<volume>29</volume>(<issue>7</issue>):<fpage>1251</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1038/jcbfm.2009.46</pub-id>
<?supplied-pmid 19401709?><pub-id pub-id-type="pmid">19401709</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref010">
                <label>10</label>
                <mixed-citation publication-type="journal"><name><surname>Abulafia</surname><given-names>DP</given-names></name>, <name><surname>de Rivero Vaccari</surname><given-names>JP</given-names></name>, <name><surname>Lozano</surname><given-names>JD</given-names></name>, <name><surname>Lotocki</surname><given-names>G</given-names></name>, <name><surname>Keane</surname><given-names>RW</given-names></name>, <name><surname>Dietrich</surname><given-names>WD</given-names></name>. <article-title>Inhibition of the inflammasome complex reduces the inflammatory response after thromboembolic stroke in mice</article-title>. <source>J Cereb Blood Flow Metab</source>. <year>2009</year>;<volume>29</volume>(<issue>3</issue>):<fpage>534</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1038/jcbfm.2008.143</pub-id> .<?supplied-pmid 19066616?><pub-id pub-id-type="pmid">19066616</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref011">
                <label>11</label>
                <mixed-citation publication-type="journal"><name><surname>Minkiewicz</surname><given-names>J</given-names></name>, <name><surname>de Rivero Vaccari</surname><given-names>JP</given-names></name>, <name><surname>Keane</surname><given-names>RW</given-names></name>. <article-title>Human astrocytes express a novel NLRP2 inflammasome</article-title>. <source>Glia</source>. <year>2013</year>;<volume>61</volume>(<issue>7</issue>):<fpage>1113</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1002/glia.22499</pub-id> .<?supplied-pmid 23625868?><pub-id pub-id-type="pmid">23625868</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref012">
                <label>12</label>
                <mixed-citation publication-type="journal"><name><surname>Goldmann</surname><given-names>T</given-names></name>, <name><surname>Tay</surname><given-names>TL</given-names></name>, <name><surname>Prinz</surname><given-names>M</given-names></name>. <article-title>Love and death: microglia, NLRP3 and the Alzheimer's brain</article-title>. <source>Cell Res</source>. <year>2013</year>;<volume>23</volume>(<issue>5</issue>):<fpage>595</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1038/cr.2013.24</pub-id>
<?supplied-pmid 23399597?><pub-id pub-id-type="pmid">23399597</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref013">
                <label>13</label>
                <mixed-citation publication-type="journal"><name><surname>Schnaars</surname><given-names>M</given-names></name>, <name><surname>Beckert</surname><given-names>H</given-names></name>, <name><surname>Halle</surname><given-names>A</given-names></name>. <article-title>Assessing beta-amyloid-induced NLRP3 inflammasome activation in primary microglia</article-title>. <source>Methods Mol Biol</source>. <year>2013</year>;<volume>1040</volume>:<fpage>1</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-62703-523-1_1</pub-id> .<?supplied-pmid 23852592?><pub-id pub-id-type="pmid">23852592</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref014">
                <label>14</label>
                <mixed-citation publication-type="journal"><name><surname>Freeman</surname><given-names>L</given-names></name>, <name><surname>Guo</surname><given-names>H</given-names></name>, <name><surname>David</surname><given-names>CN</given-names></name>, <name><surname>Brickey</surname><given-names>WJ</given-names></name>, <name><surname>Jha</surname><given-names>S</given-names></name>, <name><surname>Ting</surname><given-names>JP</given-names></name>. <article-title>NLR members NLRC4 and NLRP3 mediate sterile inflammasome activation in microglia and astrocytes</article-title>. <source>J Exp Med</source>. <year>2017</year>;<volume>214</volume>(<issue>5</issue>):<fpage>1351</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20150237</pub-id>
<?supplied-pmid 28404595?><pub-id pub-id-type="pmid">28404595</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref015">
                <label>15</label>
                <mixed-citation publication-type="journal"><name><surname>Adamczak</surname><given-names>SE</given-names></name>, <name><surname>de Rivero Vaccari</surname><given-names>JP</given-names></name>, <name><surname>Dale</surname><given-names>G</given-names></name>, <name><surname>Brand</surname><given-names>FJ</given-names></name>, 3rd, Nonner D, Bullock MR, <etal>et al</etal><article-title>Pyroptotic neuronal cell death mediated by the AIM2 inflammasome</article-title>. <source>J Cereb Blood Flow Metab</source>. <year>2014</year>;<volume>34</volume>(<issue>4</issue>):<fpage>621</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/jcbfm.2013.236</pub-id>
<?supplied-pmid 24398937?><pub-id pub-id-type="pmid">24398937</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref016">
                <label>16</label>
                <mixed-citation publication-type="journal"><name><surname>Heneka</surname><given-names>MT</given-names></name>, <name><surname>McManus</surname><given-names>RM</given-names></name>, <name><surname>Latz</surname><given-names>E</given-names></name>. <article-title>Inflammasome signalling in brain function and neurodegenerative disease</article-title>. <source>Nat Rev Neurosci</source>. <year>2018</year>;<volume>19</volume>(<issue>10</issue>):<fpage>610</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1038/s41583-018-0055-7</pub-id> .<?supplied-pmid 30206330?><pub-id pub-id-type="pmid">30206330</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref017">
                <label>17</label>
                <mixed-citation publication-type="journal"><name><surname>Cai</surname><given-names>X</given-names></name>, <name><surname>Xu</surname><given-names>H</given-names></name>, <name><surname>Chen</surname><given-names>ZJ</given-names></name>. <article-title>Prion-Like Polymerization in Immunity and Inflammation</article-title>. <source>Cold Spring Harb Perspect Biol</source>. <year>2017</year>;<volume>9</volume>(<issue>4</issue>). <pub-id pub-id-type="doi">10.1101/cshperspect.a023580</pub-id> .<?supplied-pmid 27881448?><pub-id pub-id-type="pmid">27881448</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref018">
                <label>18</label>
                <mixed-citation publication-type="journal"><name><surname>de Rivero Vaccari</surname><given-names>JP</given-names></name>, <name><surname>Dietrich</surname><given-names>WD</given-names></name>, <name><surname>Keane</surname><given-names>RW</given-names></name>. <article-title>Activation and regulation of cellular inflammasomes: gaps in our knowledge for central nervous system injury</article-title>. <source>J Cereb Blood Flow Metab</source>. <year>2014</year>;<volume>34</volume>(<issue>3</issue>):<fpage>369</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1038/jcbfm.2013.227</pub-id>
<?supplied-pmid 24398940?><pub-id pub-id-type="pmid">24398940</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref019">
                <label>19</label>
                <mixed-citation publication-type="journal"><name><surname>Kerr</surname><given-names>N</given-names></name>, <name><surname>De Rivero Vaccari</surname><given-names>JP</given-names></name>, <name><surname>Abbassi</surname><given-names>S</given-names></name>, <name><surname>Kaur</surname><given-names>H</given-names></name>, <name><surname>Zambrano</surname><given-names>R</given-names></name>, <name><surname>Wu</surname><given-names>S</given-names></name>, <etal>et al</etal><article-title>Traumatic Brain Injury-Induced Acute Lung Injury: Evidence for Activation and Inhibition of a Neural-Respiratory-Inflammasome Axis</article-title>. <source>J Neurotrauma</source>. <year>2018</year><pub-id pub-id-type="doi">10.1089/neu.2017.5430</pub-id> .<?supplied-pmid 29648974?><pub-id pub-id-type="pmid">29648974</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref020">
                <label>20</label>
                <mixed-citation publication-type="journal"><name><surname>de Rivero Vaccari</surname><given-names>JP</given-names></name>, <name><surname>Brand</surname><given-names>F</given-names><suffix>3rd</suffix></name>, <name><surname>Adamczak</surname><given-names>S</given-names></name>, <name><surname>Lee</surname><given-names>SW</given-names></name>, <name><surname>Perez-Barcena</surname><given-names>J</given-names></name>, <name><surname>Wang</surname><given-names>MY</given-names></name>, <etal>et al</etal><article-title>Exosome-mediated inflammasome signaling after central nervous system injury</article-title>. <source>J Neurochem</source>. <year>2016</year>;<volume>136</volume><issue>Suppl 1</issue>:<fpage>39</fpage>–<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1111/jnc.13036</pub-id>
<?supplied-pmid 25628216?><pub-id pub-id-type="pmid">25628216</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref021">
                <label>21</label>
                <mixed-citation publication-type="journal"><name><surname>de Rivero Vaccari</surname><given-names>JP</given-names></name>, <name><surname>Dietrich</surname><given-names>WD</given-names></name>, <name><surname>Keane</surname><given-names>RW</given-names></name>. <article-title>Therapeutics targeting the inflammasome after central nervous system injury</article-title>. <source>Transl Res</source>. <year>2016</year>;<volume>167</volume>(<issue>1</issue>):<fpage>35</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/j.trsl.2015.05.003</pub-id>
<?supplied-pmid 26024799?><pub-id pub-id-type="pmid">26024799</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref022">
                <label>22</label>
                <mixed-citation publication-type="journal"><name><surname>Brand</surname><given-names>FJ</given-names><suffix>3rd</suffix></name>, <name><surname>Forouzandeh</surname><given-names>M</given-names></name>, <name><surname>Kaur</surname><given-names>H</given-names></name>, <name><surname>Travascio</surname><given-names>F</given-names></name>, <name><surname>de Rivero Vaccari</surname><given-names>JP</given-names></name>. <article-title>Acidification changes affect the inflammasome in human nucleus pulposus cells</article-title>. <source>J Inflamm (Lond)</source>. <year>2016</year>;<volume>13</volume>(<issue>1</issue>):<fpage>29</fpage><pub-id pub-id-type="doi">10.1186/s12950-016-0137-0</pub-id><?supplied-pmid 27563282?><pub-id pub-id-type="pmid">27563282</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref023">
                <label>23</label>
                <mixed-citation publication-type="journal"><name><surname>Keane</surname><given-names>RW</given-names></name>, <name><surname>Dietrich</surname><given-names>WD</given-names></name>, <name><surname>de Rivero Vaccari</surname><given-names>JP</given-names></name>. <article-title>Inflammasome Proteins As Biomarkers of Multiple Sclerosis</article-title>. <source>Front Neurol</source>. <year>2018</year>;<volume>9</volume>:<fpage>135</fpage><pub-id pub-id-type="doi">10.3389/fneur.2018.00135</pub-id><?supplied-pmid 29615953?><pub-id pub-id-type="pmid">29615953</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref024">
                <label>24</label>
                <mixed-citation publication-type="journal"><name><surname>Adamczak</surname><given-names>S</given-names></name>, <name><surname>Dale</surname><given-names>G</given-names></name>, <name><surname>de Rivero Vaccari</surname><given-names>JP</given-names></name>, <name><surname>Bullock</surname><given-names>MR</given-names></name>, <name><surname>Dietrich</surname><given-names>WD</given-names></name>, <name><surname>Keane</surname><given-names>RW</given-names></name>. <article-title>Inflammasome proteins in cerebrospinal fluid of brain-injured patients as biomarkers of functional outcome: clinical article</article-title>. <source>J Neurosurg</source>. <year>2012</year>;<volume>117</volume>(<issue>6</issue>):<fpage>1119</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.3171/2012.9.JNS12815</pub-id>
<?supplied-pmid 23061392?><pub-id pub-id-type="pmid">23061392</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref025">
                <label>25</label>
                <mixed-citation publication-type="journal"><name><surname>Hyder</surname><given-names>AA</given-names></name>, <name><surname>Wunderlich</surname><given-names>CA</given-names></name>, <name><surname>Puvanachandra</surname><given-names>P</given-names></name>, <name><surname>Gururaj</surname><given-names>G</given-names></name>, <name><surname>Kobusingye</surname><given-names>OC</given-names></name>. <article-title>The impact of traumatic brain injuries: a global perspective</article-title>. <source>NeuroRehabilitation</source>. <year>2007</year>;<volume>22</volume>(<issue>5</issue>):<fpage>341</fpage>–<lpage>53</lpage>. .<?supplied-pmid 18162698?><pub-id pub-id-type="pmid">18162698</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref026">
                <label>26</label>
                <mixed-citation publication-type="journal"><name><surname>Blennow</surname><given-names>K</given-names></name>, <name><surname>Brody</surname><given-names>DL</given-names></name>, <name><surname>Kochanek</surname><given-names>PM</given-names></name>, <name><surname>Levin</surname><given-names>H</given-names></name>, <name><surname>McKee</surname><given-names>A</given-names></name>, <name><surname>Ribbers</surname><given-names>GM</given-names></name>, <etal>et al</etal><article-title>Traumatic brain injuries</article-title>. <source>Nat Rev Dis Primers</source>. <year>2016</year>;<volume>2</volume>:<fpage>16084</fpage><pub-id pub-id-type="doi">10.1038/nrdp.2016.84</pub-id> .<?supplied-pmid 27853132?><pub-id pub-id-type="pmid">27853132</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref027">
                <label>27</label>
                <mixed-citation publication-type="journal"><name><surname>Teasdale</surname><given-names>G</given-names></name>, <name><surname>Maas</surname><given-names>A</given-names></name>, <name><surname>Lecky</surname><given-names>F</given-names></name>, <name><surname>Manley</surname><given-names>G</given-names></name>, <name><surname>Stocchetti</surname><given-names>N</given-names></name>, <name><surname>Murray</surname><given-names>G</given-names></name>. <article-title>The Glasgow Coma Scale at 40 years: standing the test of time</article-title>. <source>Lancet Neurol</source>. <year>2014</year>;<volume>13</volume>(<issue>8</issue>):<fpage>844</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(14)70120-6</pub-id> .<?supplied-pmid 25030516?><pub-id pub-id-type="pmid">25030516</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref028">
                <label>28</label>
                <mixed-citation publication-type="journal"><name><surname>Bazarian</surname><given-names>JJ</given-names></name>, <name><surname>Biberthaler</surname><given-names>P</given-names></name>, <name><surname>Welch</surname><given-names>RD</given-names></name>, <name><surname>Lewis</surname><given-names>LM</given-names></name>, <name><surname>Barzo</surname><given-names>P</given-names></name>, <name><surname>Bogner-Flatz</surname><given-names>V</given-names></name>, <etal>et al</etal><article-title>Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre observational study</article-title>. <source>Lancet Neurol</source>. <year>2018</year><pub-id pub-id-type="doi">10.1016/S1474-4422(18)30231-X</pub-id> .<?supplied-pmid 30054151?><pub-id pub-id-type="pmid">30054151</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref029">
                <label>29</label>
                <mixed-citation publication-type="journal"><name><surname>Irrera</surname><given-names>N</given-names></name>, <name><surname>Pizzino</surname><given-names>G</given-names></name>, <name><surname>Calo</surname><given-names>M</given-names></name>, <name><surname>Pallio</surname><given-names>G</given-names></name>, <name><surname>Mannino</surname><given-names>F</given-names></name>, <name><surname>Fama</surname><given-names>F</given-names></name>, <etal>et al</etal><article-title>Lack of the Nlrp3 Inflammasome Improves Mice Recovery Following Traumatic Brain Injury</article-title>. <source>Front Pharmacol</source>. <year>2017</year>;<volume>8</volume>:<fpage>459</fpage><pub-id pub-id-type="doi">10.3389/fphar.2017.00459</pub-id><?supplied-pmid 28769794?><pub-id pub-id-type="pmid">28769794</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref030">
                <label>30</label>
                <mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>HD</given-names></name>, <name><surname>Li</surname><given-names>W</given-names></name>, <name><surname>Chen</surname><given-names>ZR</given-names></name>, <name><surname>Hu</surname><given-names>YC</given-names></name>, <name><surname>Zhang</surname><given-names>DD</given-names></name>, <name><surname>Shen</surname><given-names>W</given-names></name>, <etal>et al</etal><article-title>Expression of the NLRP3 inflammasome in cerebral cortex after traumatic brain injury in a rat model</article-title>. <source>Neurochem Res</source>. <year>2013</year>;<volume>38</volume>(<issue>10</issue>):<fpage>2072</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1007/s11064-013-1115-z</pub-id> .<?supplied-pmid 23892989?><pub-id pub-id-type="pmid">23892989</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref031">
                <label>31</label>
                <mixed-citation publication-type="journal"><name><surname>Xu</surname><given-names>X</given-names></name>, <name><surname>Yin</surname><given-names>D</given-names></name>, <name><surname>Ren</surname><given-names>H</given-names></name>, <name><surname>Gao</surname><given-names>W</given-names></name>, <name><surname>Li</surname><given-names>F</given-names></name>, <name><surname>Sun</surname><given-names>D</given-names></name>, <etal>et al</etal><article-title>Selective NLRP3 inflammasome inhibitor reduces neuroinflammation and improves long-term neurological outcomes in a murine model of traumatic brain injury</article-title>. <source>Neurobiol Dis</source>. <year>2018</year>;<volume>117</volume>:<fpage>15</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2018.05.016</pub-id> .<?supplied-pmid 29859317?><pub-id pub-id-type="pmid">29859317</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref032">
                <label>32</label>
                <mixed-citation publication-type="journal"><name><surname>Ismael</surname><given-names>S</given-names></name>, <name><surname>Nasoohi</surname><given-names>S</given-names></name>, <name><surname>Ishrat</surname><given-names>T</given-names></name>. <article-title>MCC950, the Selective Inhibitor of Nucleotide Oligomerization Domain-Like Receptor Protein-3 Inflammasome, Protects Mice against Traumatic Brain Injury</article-title>. <source>J Neurotrauma</source>. <year>2018</year>;<volume>35</volume>(<issue>11</issue>):<fpage>1294</fpage>–<lpage>303</lpage>. <pub-id pub-id-type="doi">10.1089/neu.2017.5344</pub-id>
<?supplied-pmid 29295651?><pub-id pub-id-type="pmid">29295651</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref033">
                <label>33</label>
                <mixed-citation publication-type="journal"><name><surname>Ge</surname><given-names>X</given-names></name>, <name><surname>Li</surname><given-names>W</given-names></name>, <name><surname>Huang</surname><given-names>S</given-names></name>, <name><surname>Yin</surname><given-names>Z</given-names></name>, <name><surname>Xu</surname><given-names>X</given-names></name>, <name><surname>Chen</surname><given-names>F</given-names></name>, <etal>et al</etal><article-title>The pathological role of NLRs and AIM2 inflammasome-mediated pyroptosis in damaged blood-brain barrier after traumatic brain injury</article-title>. <source>Brain Res</source>. <year>2018</year><pub-id pub-id-type="doi">10.1016/j.brainres.2018.06.008</pub-id> .<?supplied-pmid 29886252?><pub-id pub-id-type="pmid">29886252</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref034">
                <label>34</label>
                <mixed-citation publication-type="journal"><name><surname>Geng</surname><given-names>F</given-names></name>, <name><surname>Ma</surname><given-names>Y</given-names></name>, <name><surname>Xing</surname><given-names>T</given-names></name>, <name><surname>Zhuang</surname><given-names>X</given-names></name>, <name><surname>Zhu</surname><given-names>J</given-names></name>, <name><surname>Yao</surname><given-names>L</given-names></name>. <article-title>Effects of Hyperbaric Oxygen Therapy on Inflammasome Signaling after Traumatic Brain Injury</article-title>. <source>Neuroimmunomodulation</source>. <year>2016</year>;<volume>23</volume>(<issue>2</issue>):<fpage>122</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1159/000445689</pub-id> .<?supplied-pmid 27216735?><pub-id pub-id-type="pmid">27216735</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref035">
                <label>35</label>
                <mixed-citation publication-type="journal"><name><surname>Tomura</surname><given-names>S</given-names></name>, <name><surname>de Rivero Vaccari</surname><given-names>JP</given-names></name>, <name><surname>Keane</surname><given-names>RW</given-names></name>, <name><surname>Bramlett</surname><given-names>HM</given-names></name>, <name><surname>Dietrich</surname><given-names>WD</given-names></name>. <article-title>Effects of therapeutic hypothermia on inflammasome signaling after traumatic brain injury</article-title>. <source>J Cereb Blood Flow Metab</source>. <year>2012</year>;<volume>32</volume>(<issue>10</issue>):<fpage>1939</fpage>–<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1038/jcbfm.2012.99</pub-id>
<?supplied-pmid 22781337?><pub-id pub-id-type="pmid">22781337</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref036">
                <label>36</label>
                <mixed-citation publication-type="journal"><name><surname>Lin</surname><given-names>C</given-names></name>, <name><surname>Chao</surname><given-names>H</given-names></name>, <name><surname>Li</surname><given-names>Z</given-names></name>, <name><surname>Xu</surname><given-names>X</given-names></name>, <name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Bao</surname><given-names>Z</given-names></name>, <etal>et al</etal><article-title>Omega-3 fatty acids regulate NLRP3 inflammasome activation and prevent behavior deficits after traumatic brain injury</article-title>. <source>Exp Neurol</source>. <year>2017</year>;<volume>290</volume>:<fpage>115</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/j.expneurol.2017.01.005</pub-id> .<?supplied-pmid 28077335?><pub-id pub-id-type="pmid">28077335</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref037">
                <label>37</label>
                <mixed-citation publication-type="journal"><name><surname>Zou</surname><given-names>P</given-names></name>, <name><surname>Liu</surname><given-names>X</given-names></name>, <name><surname>Li</surname><given-names>G</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>. <article-title>Resveratrol pretreatment attenuates traumatic brain injury in rats by suppressing NLRP3 inflammasome activation via SIRT1</article-title>. <source>Mol Med Rep</source>. <year>2018</year>;<volume>17</volume>(<issue>2</issue>):<fpage>3212</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2017.8241</pub-id> .<?supplied-pmid 29257276?><pub-id pub-id-type="pmid">29257276</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref038">
                <label>38</label>
                <mixed-citation publication-type="journal"><name><surname>Ma</surname><given-names>J</given-names></name>, <name><surname>Xiao</surname><given-names>W</given-names></name>, <name><surname>Wang</surname><given-names>J</given-names></name>, <name><surname>Wu</surname><given-names>J</given-names></name>, <name><surname>Ren</surname><given-names>J</given-names></name>, <name><surname>Hou</surname><given-names>J</given-names></name>, <etal>et al</etal><article-title>Propofol Inhibits NLRP3 Inflammasome and Attenuates Blast-Induced Traumatic Brain Injury in Rats</article-title>. <source>Inflammation</source>. <year>2016</year>;<volume>39</volume>(<issue>6</issue>):<fpage>2094</fpage>–<lpage>103</lpage>. <pub-id pub-id-type="doi">10.1007/s10753-016-0446-8</pub-id> .<?supplied-pmid 27696022?><pub-id pub-id-type="pmid">27696022</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref039">
                <label>39</label>
                <mixed-citation publication-type="journal"><name><surname>Kerr</surname><given-names>N</given-names></name>, <name><surname>Garcia-Contreras</surname><given-names>M</given-names></name>, <name><surname>Abbassi</surname><given-names>S</given-names></name>, <name><surname>Mejias</surname><given-names>NH</given-names></name>, <name><surname>Desousa</surname><given-names>BR</given-names></name>, <name><surname>Ricordi</surname><given-names>C</given-names></name>, <etal>et al</etal><article-title>Inflammasome Proteins in Serum and Serum-Derived Extracellular Vesicles as Biomarkers of Stroke</article-title>. <source>Front Mol Neurosci</source>. <year>2018</year>;<volume>11</volume>:<fpage>309</fpage><pub-id pub-id-type="doi">10.3389/fnmol.2018.00309</pub-id><?supplied-pmid 30233311?><pub-id pub-id-type="pmid">30233311</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0210128.ref040">
                <label>40</label>
                <mixed-citation publication-type="journal"><name><surname>Syed</surname><given-names>SA</given-names></name>, <name><surname>Beurel</surname><given-names>E</given-names></name>, <name><surname>Loewenstein</surname><given-names>DA</given-names></name>, <name><surname>Lowell</surname><given-names>JA</given-names></name>, <name><surname>Craighead</surname><given-names>WE</given-names></name>, <name><surname>Dunlop</surname><given-names>BW</given-names></name>, <etal>et al</etal><article-title>Defective Inflammatory Pathways in Never-Treated Depressed Patients Are Associated with Poor Treatment Response</article-title>. <source>Neuron</source>. <year>2018</year>;<volume>99</volume>(<issue>5</issue>):<fpage>914</fpage>–<lpage>24</lpage> e3. <pub-id pub-id-type="doi">10.1016/j.neuron.2018.08.001</pub-id>
<?supplied-pmid 30146307?><pub-id pub-id-type="pmid">30146307</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
